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ABSTRACT
COAGULATION FACTOR XIII A: BIOCHEMICAL PROPERTIES UNDERLYING
PHYSIOLOGICAL FUNCTION
Boris Anokhin
November 20, 2018

Factor XIIIA (FXIIIA) is a transglutaminase that crosslinks intra- and extracellular
protein substrates. FXIIIA is expressed as an inactive zymogen, and during blood
coagulation, it is activated by removal of an activation peptide by thrombin. The resulting
plasma transglutaminase forms isopeptide bonds between α and γ chains of fibrin, thus
stabilizing the clot. No such proteolytic FXIIIA activation is known to occur in other tissues
(i.e. bone) or the intracellular form of FXIIIA. For those locations, FXIIIA is assumed
instead to undergo activation by Ca2+ ions.
FXIIIA is the only transglutaminase existing as a dimer in zymogen form. The
oligomeric state of the active enzyme remains controversial, and the present work
commenced with addressing this issue. The results of size exclusion chromatography and
analytical ultracentrifugation confirmed a dimeric state for zymogen and, for the first time,
indicated a monomeric state for the active FXIIIA in solution. Analysis of FXIIIA mutants
with impaired dimeric interfaces stressed the importance of dimeric state in maintaining
zymogen stability in solution. Comparing sedimentation properties of proteolytically and
nonproteolytically activated FXIIIA suggested conformational and functional differences
v

between the two forms. Those differences were further assessed in a series of catalytic
activity studies. Kinetic analysis revealed affinity for the glutamine substrate was higher
for proteolytically activated FXIIIA than for FXIIIA activated by high mM Ca2+.
FXIIIA proteolytic activation was investigated in a context of fibrin clotting. The
V34X FXIIIA variants were generated using site-directed mutagenesis and recombinantly
expressed in Escherichia coli. Those variants were ranked in terms of their activation rates
by thrombin L34>>V34>F34>>W34. In a series of SDS-PAGE and clot turbidity assays,
the proteolytic activation rates of FXIIIA variants were correlated with the extent of
covalent fibrin crosslinking. The V34X FXIIIA variants were administered into murine
FXIIIA-deficient plasma. Scanning electron microscopy of the whole plasma clots
revealed morphological evidence for incorporation of nonfibrous protein into the clot. The
magnitude of this incorporation correlated with the FXIIIA activation rate. Overall, the
presented research fills in critical gaps in previously identified FXIIIA biochemical
attributes and expands the understanding of FXIIIA physiological function.
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CHAPTER 1

INTRODUCTION
Coagulation Factor XIII A (FXIIIA) is a member of the transglutaminase family of
enzymes (protein glutamine:amine γ-glutamyltransferase, EC 2.3.2.13) that crosslinks
protein substrates via an isopeptide bond in a Ca2+-dependent manner. FXIIIA has been a
subject of biochemical research for almost a century. As physiological knowledge on FXIII
expands, it becomes apparent that beyond serving as a key player of the coagulation
system, FXIIIA functions in wound healing, bone tissue dynamics, and even signaling
processes (1,2). Being involved in an array of intra- and extracellular events, FXIIIA is
implicated in associated pathological conditions and has thus become an attractive target
for pharmacological intervention. Developing therapeutic regimes that effectively manage
FXIIIA in its particular physiological environments definitely warrants a more in depth
understanding of FXIIIA function in such locations. The purpose of this introductory
chapter is to define the physiological niche of FXIIIA and to provide a brief overview of
FXIIIA structural attributes. Goals of the current research project are presented in the
conclusion.

FXIIIA is expressed as an inactive zymogen in cells of bone marrow origin,
predominantly in megacaryocytes, monocytes, and macrophages (2-5). The intracellular
distribution and functions of FXIII have been studied extensively during the last three
1

decades (5). Megakaryocytes synthesize a large amount of FXIIIA. In the early stage of
megakaryocyte development, FXIIIA is diffusely distributed in the cytoplasm. As the
megakaryocyte maturates, FXIIIA is predominantly localized in a peripheral part of the
cytoplasm and is then packaged in large quantities into the budding platelets. At the late
megakaryocyte stage, FXIIIA is present in significantly lower quantities (6).
Monocytes also produce FXIIIA, and as they differentiate into macrophages, the
FXIIIA expression levels increase (7). In macrophages, FXIII accumulates around
cytoplasmic vacuoles and in pseudopods (8) and even appears in the nucleus (9). Nuclear
FXIIIA is thought to participate in chromatin remodeling and cell differentiation. In the
cytoplasm, certain cytoskeletal proteins serve as FXIIIA substrates, particularly actin and
myosin, which are elements of the contractile locomotory system of the cells. The
cytoskeletal system is involved in the phagocytosis function of monocytes and
macrophages (5).

The first described and most studied function of FXIII is as a blood coagulation
factor. Histologically, blood is viewed as a specialized connective tissue. Red blood cells
(RBC, erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes)
constitute formed elements, and plasma is a liquid extracellular medium of this tissue.
Since the blood circulates under pressure in the vascular system, an impairment to the
integrity of that system, such as damage to a blood vessel, would result in bleeding.
Provided the damage is not severe, the clotting system prevents excessive blood loss. This
system is comprised of twelve coagulation factors (10), of which eleven are soluble plasma
proteins (factors I – III, V, and VII – XIII; there is no factor VI) and one is the Ca2+ ion
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(factor IV).
The protein factors circulate in plasma as inactive precursor forms and may be
activated in two different ways: the tissue factor (TF) pathway and the contact pathway
(Fig. 1) (10). Tissue damage results in exposure of the TF expressing cells to the blood
plasma. TF forms a complex with coagulation factor VIIa, which then activates factor IX
through limited proteolysis. Factor IX in turn activates factor X, through proteolysis as
well. The TF pathway is also called the extrinsic pathway, because it requires interaction
with the extrinsic TF. The contact (intrinsic) pathway is triggered without presentation of
the TF. This pathway is initiated when plasma comes in the contact with a certain type of
surface. Such interaction results in proteolytic activation of coagulation factor XII and the
downstream factors, including factor X.

Fig. 1. Blood coagulation cascade. Roman numerals represent coagulation factors, letter ‘a’ denotes activated
factors. HK – high molecular weight kininogen, TF – tissue factor, PL – phospholipid. Adapted from
www.enzymeresearch.com.
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Thus, it could be seen that once the coagulation process is activated by one of the
pathways, a series of proteolytic events then leads to generation of factor X. Factor X
activates a serine protease thrombin (factor IIa). Thrombin proteolytically converts
fibrinogen (factor I) to fibrin (11,12), and in parallel, activates FXIIIA (4,13,14). As the
soluble fibrin undergoes self-polymerization into an insoluble fiber network, the
transglutaminase FXIIIA introduces covalent crosslinks between the fibrin molecules
within this network, thereby increasing its mechanical stability (2-4,15). FXIIIA also
crosslinks other proteins into the fibrin network; fourteen FXIIIA protein substrates were
identified in clot proteomics (16). Importantly, FXIIIA-mediated incorporation of α2antiplasmin imparts resistance of the fibrin network to fibrinolysis by the protease plasmin
(2,3,15). The fibrin net retains RBC that further increase overall mechanical stability of the
blood clot and reduce its porosity. Entrapment of those cells in the clot has been strongly
correlated with FXIIIA activity (17); however, no evidence of actual RBC crosslinking to
the fibrin matrix has been reported. It is likely, therefore, that the RBC retention is mediated
by the mechanical stability of the crosslinked fibrin network preventing escape of RBC
with the incessant blood flow. Platelets are also incorporated in the fibrin clot but, unlike
RBC, they play a more active role in the clot dynamics by coordinating the clot retraction.
Their surface protein, the integrin αIIbβ3, anchors onto the fibrin mesh. As the platelet
internal cytoskeleton undergoes reorganization (a FXIIIA-mediated process), it transmits
the contractile force onto the extracellular fibrin fibers. This process ultimately results in
reducing the clot volume due to compaction (18,19). The compressed clot is even more
impenetrable and provides a temporary plug that seals the damaged vessel.
The extrinsic TF coagulation pathway is proposed to dominate in the early stages
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of bleeding cessation upon vascular tissue damage. The intrinsic contact pathway has been
regarded as part of mostly pathological processes (10); however, a recent review suggests
its physiological role during the late stages of coagulation (19). After the plateletmoderated clot retraction, a series of tissue repair events occur. In these events, FXIIIA
crosslinks extracellular matrix (ECM) proteins fibronectin, vitronectin, thrombospondin,
and collagen, thus providing the scaffold for vessel repair. Furthermore, FXIIIA-catalyzed
crosslinking of the vascular endothelial growth factor receptor to the integrin αvβ3 at the
endothelial cell surface promotes cell motility and proliferation, thus initiating
angiogenesis (2,20,21).
At a later stage of angiogenesis, the crosslinked protein scaffold must undergo
degradation to finalize tissue repair. The fibrinolytic system with the key player serine
protease plasmin is responsible for this degradation (22,23). The activation of plasmin is
enhanced at the fibrin surface (23). At the same time, the efficiency of plasmin-mediated
fibrinolysis strongly depends on the density of the fibrin clot. This dependence is two-fold:
the contracted clots are less penetrable for plasmin and the concentration of the crosslinked
plasmin inhibitor α2-antiplasmin is higher in a denser clot (18). FXIIIA function enhances
fibrin density and increases incorporation of α2-antiplasmin and, therefore, has an impact
on activity of the fibrinolytic machinery (24).

Described so far is a normal physiological presentation of blood coagulation,
known as hemostasis. Coagulation may also proceed inside the blood vessels as part of
pathological process called thrombosis (10). Thromboses account for the major part of
coagulation-associated morbidity and mortality (15,17,24-27). Intravascular coagulation
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may occur in arteries and veins, and the central etiological event in both types of thrombosis
is the deposition of fibrin. FXIIIA contribution to venous thrombosis is coagulation-related
and results in stabilization of the thrombus. In arterial thrombosis, FXIIIA involvement is
somewhat more complicated. Similar to venous thrombosis, the crosslinking activity
occurring in the arterial thrombogenesis defines the FXIIIA prothrombotic effect.
However, the FXIIIA function in post-thrombotic arterial events, such as myocardial
infarction, has been correlated with better outcomes. These ameliorations are promoted by
FXIIIA-mediated repair of the infarcted tissue.

The intrinsic (contact) pathway of coagulation is activated on the surface of certain
bacteria entering the bloodstream (28-30). The resultant FXIIIA activity thus ultimately
leads to sequestration of an infectious agent within a fibrin clot and prevents its spreading
from the site of infection (21,31). This FXIIIA function is in part fulfilled by creating a
stronger fibrin network. In addition, FXIIIA directly crosslinks the bacterial cells to fibrin,
through specific surface proteins in a serotype-dependent manner. A good illustration of
the FXIII protective role was provided by a study (32) where FXIII deficient mice
developed a more severe systemic inflammatory response to some streptococcal infections.
This severity was reduced upon administration of exogeneous FXIIIA. While in general
FXIIIA activity prevents the spreading of pathogens from the infection site, a fascinating
exception is Staphylococcus aureus. A majority of clinical S. aureus strains produce a
hemostatic factor coagulase whose ability to bind fibrinogen and to activate thrombin
results in fibrin deposition at the infection site (33,34). Confined within the fibrin clot,
S. aureus is protected from the host innate immune system and, unlike opportunistic
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pathogens, utilizes the fibrin matrix for replication and persistence, thus taking advantage
of the coagulation system as part of its virulence strategy (35).

Systemic inflammation also activates the coagulation cascade. Extreme
inflammatory complications of infection, such as sepsis, result in hyperactivity of the
clotting system (28). In a proteomic study, almost the entire complement inflammatory
system has been shown to be a target for FXIIIA (16). However, the reports examining
FXIIIA interaction with those substrates are scarce. In general, increased levels of FXIIIA
crosslinking result in extensive fibrin deposition throughout the microvasculature. This
condition, referred to as disseminated intravascular coagulation (DIC), results in cessation
of the organ blood supply and ultimately, organ failure (36). At the same time, ongoing
consumption of the clotting factors and platelets in DIC together with hyperfibrinolysis,
may result in excessive bleeding. Dysregulation of the coagulation cascade also plays an
etiologic role in other inflammatory diseases including asthma, rheumatoid arthritis, etc.,
through excessive deposition of fibrin (37-41).

Coagulation is tightly interconnected with oncological events (42-44). Tumor cells
constitutively express TF and expose it on the surface thereby activating the coagulation
system. Tumor procoagulant activity is also manifested through expression of a so-called
cancer procoagulant that directly activates factor X. Thrombotic events significantly
contribute to malignancy-associated complications, and the risk of developing venous
thrombotic embolism in cancer patients is increased seven-fold compared to the general
population. Analogous to septic complications, DIC-related severe hemorrhages are often
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observed in cancer. The DIC is particularly associated with acute leukemias.
Besides the devastating thrombotic and hemorrhagic complications, the
coagulation system is implicated in tumor neoangiogenesis. The mechanism of coagulation
system neoangiogenic function is essentially the same as outlined above for post vascular
injury events, except here it becomes a part of the tumor progression. Localized fibrin
deposition enhances adhesion of the tumor cells to the endothelium, facilitating the
metastatic process. Furthermore, the tumor cells activate platelets, and the resulting tumor
cell-platelet thrombi support metastasis formation by shielding the tumor from the innate
immune system, an outcome similar to that aforementioned for S. aureus.

Apart from serving in the coagulation system, FXIIIA fulfills coagulationindependent functions. Although not recognized enough and even less understood, a unique
place for FXIIIA is in the extracellular matrix of osseous tissue. The bone mass is regulated
by the bone tissue remodeling. This remodeling occurs constantly at 1–2 million sites in an
adult skeleton (45). Coordination of this process involves multiple physiological pathways
that are beyond the scope of this chapter. In a simplified approach, the bone dynamics
involves reciprocal activity of bone-resorbing osteoclasts and bone-forming osteoblasts
(46). Remodeling is initiated by osteoclasts secreting HCl into the resorptive space,
yielding an extracellular pH of <4.5 and very high (on the order of 40 mM) local
concentrations of Ca2+. In response to such Ca2+ levels, osteoblasts migrate to the site of
bone resorption (45). Osteoblasts generate ECM that forms a substratum to support cell
attachment and regulates mineralization. The bone ECM consists primarily of type 1
collagen (COL1), and plasma fibronectin (pFN) is a major component of noncollageneous
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bone matrix (47-49).
The reports on FXIIIA function in the bone remodeling are somewhat
contradictory. They agree, however, that functions of FXIIIA and Transglutaminase 2
(TG2) in the bone ECM overlap. A single deficiency of either protein did not result in an
overt bone phenotype in murine models, which was attributed to a compensatory effect of
the other transglutaminase (50-52). A study employing murine model of double FXIIIA
and TG2 deficiency concluded that neither transglutaminase was required for bone
mineralization (53). Moreover in another study, inhibition of the transglutaminase activity
was associated with reduced osteoclastogenesis and better outcome in collagen induced
arthritis (41). However, a work examining the maintaince of bone mass and remodeling
activity of bone cells, revealed that together with TG2, FXIIIA was a negative regulator of
osteoclastogenesis. Absence of TG2 and FXIIIA led to overexpression

of

osteoclastogenesis-promoting transglutaminase 1, whose inhibition likely reduced bone
loss in the pathogenesis of arthritis (49,54).
Thus, FXIIIA activity is currently known to mediate accumulation and crosslinking
of the pFN in the bone ECM (55). The pFN accumulation enhances proliferation and
differentiation of the osteoblasts. Plasma membrane-associated FXIIIA promotes secretion
of COL1 by osteoblasts (56). Extracellularly, FXIIIA and TG2 coordinate COL1 matrix
deposition thereby promoting bone mineralization (49,51,54,56,57).
A cartoon in Fig. 2 summarizes some aspects of the physiological presence of
FXIIIA in cells, bone tissue, and blood plasma.
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Fig. 2. Physiological niche of FXIIIA. FXIIIA begins its journey in the cells of bone marrow. The myeloid
stem cells undergo differentiation events (denoted by arrows): erythropoiesis that results in formation of red
blood cells and thrombopoiesis resulting in megakaryocytes. Megakaryocytes synthesize large amount of
FXIIIA and package it into the platelets. Leukopoiesis leads to formation of lymphocytes, granulocytes and
monocytes, with the latter being the most relevant to the subject of present review. FXIIIA is the only
transglutaminase expressed in monocytes, and the ruptured monocytes have been assumed to serve as a
source of plasma FXIIIA. The FXIIIA expression increases during differentiation of macrophages. On the
contrary, differentiation of osteoclasts is accompanied by decrease in FXIIIA levels. As part of tissue
remodeling, osteoclasts mediate bone resorption. Osteoblasts differentiate from the mesenchymal stem cells,
and during that differentiation FXIIIA expression is upregulated. Osteoblasts are responsible for the
deposition of ECM and subsequent mineralization of bone.

10

Current view on the structure and activation of FXIIIA
As mentioned in the beginning of this chapter, FXIIIA has been a subject of
biochemical research for almost a century. The first report suggesting covalent stabilization
of fibrin appeared in 1923. Barkan and Gaspar (Barkan G., Gaspar A. Zur Frage der
Reversibilitä t der Fibringerinnung II. Biochem. Ztschr. 1923, from (1)) observed that the
fibrin clots formed in the presence of Ca2+ became insoluble in weak bases. A couple of
decades later, Robbins proposed the existence of a “serum factor” rendering the clots
insoluble (Robbins K.C. A study on the conversion of fibrinogen to fibrin. Am. J. Physiol.
1944, from (1)). Laki and Lorand (58) later named the protein “fibrin stabilizing factor”.
The name Factor XIII appeared in the literature in the 1960s.
FXIIIA catalyzes formation of an ε-(γ-glutamyl) lysine isopeptide bond, following
a modified ping-pong mechanism shared by members of the transglutaminase family
(59,60) (Fig. 3).

Fig. 3. Mechanism of the transglutaminase reaction. During the first half-reaction the thiolate of catalytic
cysteine performs a nucleophilic attack on the carbonyl carbon of glutamine side chain, resulting in formation
of a thioester acyl-enzyme intermediate and release of ammonia. Deacylation and regeneration of the free
enzyme may proceed through acyl transfer to a primary amine such as lysine side chain (transamidation)
which results in the formation of an isopeptide bond between the glutamine and amine substrates. In the
absence of amine substrate, the thioester intermediate undergoes hydrolysis resulting in net deamidation of
the glutamine to glutamate. Adapted from (59).
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Unlike most other transglutaminases, FXIIIA is expressed as an inactive zymogen, and in
plasma, it circulates in a ~325 kDa heterotetrameric complex with carrier FXIIIB (A2B2,
the molecular weight of each A-subunit is ~83 kDa, and each FXIIIB molecule is ~79 kDa).
During blood coagulation, FXIII is activated by thrombin-mediated removal of N-terminal
activation peptides from the A-subunits followed by dissociation of the B-subunits (61) in
the presence of Ca2+ (Fig. 4).
FXIIIA exists as an A2-homodimer within the cells and, while intracellular FXIIIA
activity does figure in multiple reports, its activation in this physiological compartment is
much less understood. No intracellular proteolytic modification of FXIIIA has been found,
and the current consensus is a slow nonproteolytic activation in the presence of low
available Ca2+ concentrations (62-64). Both plasma and cellular FXIII can be activated
non-physiologically in the presence of high (>50 mM) Ca2+ (Fig. 4) Lorand (65)
demonstrated that Ca2+ is crucial for the transglutaminase activity, whereas other divalent
cations were much less effective, in the order Sr2+>Ba2+>Mg2+. This specific effect of Ca2+
could be augmented, but not replaced, by increasing ionic strength.

Fig. 4. Activation of FXIIIA. A′ - FXIIIA after cleavage of the activation peptide, A* - FXIIIA activated by
thrombin in the presence of low mM Ca2+, A° - FXIIIA activated nonproteolytically in the presence of high
mM Ca2+ (66).
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The amino acid sequence of the active site region was identified by Holbrook and
coworkers (67), and the full sequence was determined by Ichinose et al. (68). FXIIIA was
the first member of the transglutaminase family whose crystal structure was solved and,
noteworthy, this structure later served as a template for solving the structures of other
members of the transglutaminase family. Consistent with previous solution studies, the
structure by Yee and coworkers revealed two crystallographically independent A-subunits
(Fig. 5A) (69,70). The structural domains of each A-subunit include the N-terminal
activation peptide (residues 1−37), β-sandwich (38−183), catalytic core (184−515)
containing conserved transglutaminase catalytic triad C314, H373, and D396, β-barrel 1
(516−627), and β-barrel 2 (628−730). As evident from their names, the β-sandwich and the
two β-barrel domains present primarily β-elements of secondary structure. The catalytic
core domain is predominantly comprised of α-helices.
The A-subunits of FXIII are oriented in a head-to-tail fashion within the dimer. The
interface between the monomers is long and involves the β-sandwich and the catalytic core
domains, with a contact area of ~1800 Å2. The catalytic core domain of the zymogen Asubunit is shielded by the two β-barrels. The energy of interaction between the catalytic
domain and β-barrel 1 is −11 kcal/mol, and a prominent feature of this interaction is a
hydrogen bond between the sulfur of catalytic C314 and the hydroxyl group of the β-barrel
1 residue Y560. In addition, the catalytic site of each subunit is blocked by the activation
peptide of the neighboring subunit. The energy of activation peptide interaction with its
own subunit is approximately −9 kcal/mol and about −5 kcal/mol with the other subunit.
Each A subunit in the FXIII zymogen contains a Ca2+ ion (not shown) coordinated by the
main chain carbonyl oxygen of A457 and sidechain carboxylates of D348, E485, and E490.
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In addition, three cis-peptide bonds are found in FXIIIA: G410−P411, and two non-proline
cis-bonds R310−Y311 and Q425−F426 (71). A cis-trans isomerization of these bonds was
proposed to act as a conformational switch; however, no experimental evidence supporting
this hypothesis has been reported.

Fig. 5. Crystal structures of FXIIIA. (A) FXIIIA zymogen (PDB 1F13): the dimer is shown in a spacefilling model, and structural elements of the left subunit are highlighted in a ribbon representation; (B)
non-proteolytically activated FXIIIA° (PDB 4KTY): asymmetric crystal unit is shown in space-filling
with covalently bound inhibitor ZED1301 in ball-and-stick, and a single subunit - as ribbons, with the
three bound Ca2+ ions denoted as black spheres. ZED1301: Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-ProOH, (MA – Michaelis acceptor, Nle – norleucine).
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Recently, a high-resolution crystal structure of an activated FXIIIA with a
glutamine mimic inhibitor bound in the active site was described by Stieler et al. (72).
Unlike the zymogen, the structure of inhibited FXIIIA revealed that the two β-barrels and
the activation peptide moved aside (Fig. 5B), exposing the catalytic center. Besides the
previously observed Ca2+ in the zymogen, two additional Ca2+-binding sites were
described. In addition, a hydrophobic tunnel formed by side chains of W279 and W370
was observed (Fig. 6). The proposed function of this pair was to reduce the possibility of
hydrolysis of the thioester intermediate formed by catalytic C314 and the glutamine
substrate. Molecular docking experiments indicated that the lysine side chain would fit
perfectly into this tunnel.

Fig. 6. Active site of FXIIIA. The zoomed in (PDB 4KTY) active site of the activated FXIIIA° is displayed
as a surface potential representation (Pymol) with the inhibitor depicted as ball-and-stick. W279 and W370
form a hydrophobic tunnel. Dashed arrows indicate the direction of entrance of the glutamine donor (Q)
and the lysine donor (K) substrates. Depicted on the right is identical view of the FXIIIA subunit with
increased transparency for visualization of the buried Ca 2+ ions and part of the inhibitor molecule.

Thus, along with structural features, this introductory review outlines FXIIIA roles
in normal and pathological events. By no means does it cover the entire physiological
involvement of FXIIIA. The overview, however, brings awareness that FXIIIA is not solely
a blood coagulation factor. Such recognition significantly impacts the design of the
presented research project.
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RESEARCH GOALS
The ultimate purpose of the present project was to understand FXIIIA activation.
In particular, what global rearrangements does FXIIIA undergo during activation, and how
may those rearrangements affect FXIIIA function in different physiological environments?
The research can be divided into three major portions. First, FXIIIA oligomeric states were
assessed in solution as a function of the activation state. Next, dynamic and functional
implications of physiologically relevant FXIIIA activation pathways were investigated.
Finally, a special case of FXIIIA activation was further studied in the context of a fibrin
clotting model.

Rationale for studying FXIIIA oligomeric states
Zymogen FXIIIA exists as an A2 homodimer. In plasma, FXIIIA2 is found in a
complex with two carrier B-subunits (A2B2). In the coagulation cascade, thrombin cleaves
the N-terminal activation peptide from the A-subunits of FXIII, followed by Ca2+dependent dissociation of the B-subunits exposing catalytically active transglutaminase.
FXIII A2 can be activated by thrombin in the presence of low mM Ca2+. Both FXIII A2B2
and A2 can be activated non-proteolytically by >50 mM Ca2+. In early studies by Chung
and coworkers (73), thrombin-activated FXIIIA in the presence of Ca2+ appeared as a
monomer in gel filtration, but it was concluded to exist in dimeric form from sedimentation
equilibrium analysis. Thus, the active form of FXIIIA has long been considered a dimer.
In a recent work (72), however, non-proteolytically activated FXIIIA with an inhibitor
bound to the active site was proposed to exist as a monomer. The research discussed in
Chapter 4 revisits the conformational rearrangements and oligomeric states of FXIIIA in a
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solution environment.
It is believed that single amino acid substitutions have the potential to disrupt dimer
formation by the zymogen FXIIIA. A few potential candidates had been identified in
patients with severe FXIII deficiency: R260L (74), R260C (75-77), Y283C and G562R
(78) (Fig. 7). An R11Q substitution in the activation peptide (Fig. 7) was computationally
predicted to impair A2 dimer formation (79). The experiments on the mutants were
performed using cell lysates rather than purified proteins. A characteristic of all those
mutants was an extremely low expression level in eukaryotic cell lines. Employing FXIIIA
mutants as a model system, Chapter 4 discusses the importance for FXIIIA zymogen to
form a correct dimer interface.

Fig. 7. Amino acid residues in FXIIIA whose substitutions are believed to impair dimerization of the
zymogen. FXIIIA subunits are represented as ribbons, and selected residues – as molecular surfaces.

Rationale for studying different mechanisms of FXIIIA activation
The medical literature abounds with statistical research correlating FXIIIA levels
with outcomes in numerous pathological conditions. Often, however, relatively new
reports contradict conclusions of the previous publications. This issue is not unique for the
FXIIIA field and may often be attributed to the absence of experimentally confirmed cause
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and effect relationships that underlie statistically significant correlations. The lack in
establishing those relationships stresses, yet again, the incomplete understanding of FXIIIA
activation and function.
Despite century-long research, FXIIIA is still viewed primarily as a coagulation
factor. FXIIIA activation in plasma by thrombin was characterized relatively well even in
early studies (80-82). Intracellular activation had only been studied for platelet FXIIIA (6264). Nonproteolytic activation of cellular FXIIIA was experimentally shown to proceed
even in the presence of low Ca2+ levels; however, at nonphysiologically high (1 M)
concentrations of Na+ or K+. No experimental insight is currently available on the dynamic
and functional implications of low mM Ca2+-activation of FXIIIA.
FXIII activation by high (>50 mM) Ca2+, first described by Credo et al. (83), is
regarded as being nonphysiological. Previous work by the Maurer group revealed different
patterns of solvent accessibility for FXIIIA activated by thrombin and by high mM Ca2+
(84-86). Active FXIIIA could only be crystallized after nonproteolytic activation in the
presence of high Ca2+ concentration followed by irreversible inhibition (72). Although
being a static “snapshot”, this crystal structure provided a valuable and previously
unavailable view of active FXIIIA at the molecular level. The structure was later used for
computational modeling of proteolytic FXIIIA activation (87). This strategy occurred
despite previously reported structural differences between proteolytically and
nonproteolytically activated forms. Chapter 5 investigates proteolytic and nonproteolytic
activation of FXIIIA in solution, and provides insights on global conformational
differences of the resulting FXIIIA forms.
FXIIIA in the ECM has recently begun to receive considerable attention, and a few
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published studies outline the role of FXIIIA in bone tissue dynamics (47,49,54,55,57). In
an early study, Kaartinen and coworkers proposed that a 37 kDa proteolytic fragment was
a major FXIIIA form in the bone ECM (47). However, Cordell et al. (53) later identified
this fragment as transaldolase-1 and demonstrated its immunoreactivity with anti-FXIIIA
antibody. Thus far, no information is available on FXIIIA activation in this physiological
compartment, and a possible activation mechanism is discussed in Chapter 5.

Rationale for studying the effect of FXIIIA activation rate on fibrin architecture
Fibrin is the main constituent of a blood clot.
Its precursor, fibrinogen, represents a dimer of
trimers: (Aα Bβ γ)2. In the final stage of blood
coagulation, thrombin cleaves fibrinopeptides A and
B from fibrinogen, forming fibrin and initiating
polymerization of fibrin monomers into fibers
(Fig. 8). At the same time, activated FXIIIA catalyzes
formation of covalent bonds between γ-γ, γ-α, and αα chains of adjacent fibrin molecules. Crosslinking of
Fig. 8. Schematic representation of
fibrin fiber formation

α2-antiplasmin into the fibrin network makes it
mechanically stronger and resistant to fibrinolysis.

Interestingly, a V34L polymorphism in the activation peptide of FXIIIA was associated
with altered clot structure, more precisely, with thinner fibrin fibers (88). It was recently
shown (89) that the L34 variant increased fibrin cross-linking in a murine model of
thrombosis. A noticeable feature of the L34 variant is its enhanced cleavage by thrombin,
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leading to the faster activation of FXIIIA. Kinetic studies performed in the Maurer lab (9096) employed an HPLC assay on activation peptide fragments (residues 28−41) and
confirmed that the L34 variant was hydrolyzed by thrombin more efficiently than the more
common V34. A series of additional activation peptide substitutions was generated with an
extended range of the cleavage rates. The rates of FXIIIA proteolytic activation were
predicted to affect the properties of fibrin clot. The research in Chapter 6 utilizes full length
V34X protein variants to test this prediction.
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CHAPTER 2
A REVIEW OF SPECIAL TECHNIQUES EMPLOYED IN THE CURRENT
RESEARCH PROJECT

Biochemists are extremely fortunate to have a variety of methods at their disposal
nowadays. Techniques such as gel electrophoresis, spectrophotometry, chromatography
etc. have been routinely employed to study proteins, and the current project was not an
exception.

Two

instrumental

approaches

employed

in

this

work,

analytical

ultracentrifugation and scanning electron microscopy, are less frequently utilized in
biochemical research and deserve a special discussion. The present brief review is intended
to familiarize the reader with the principles behind these two techniques.

Analytical Ultracentrifugation
Analytical ultracentrifugation (AUC) is a universal method for characterization of
macromolecules (proteins, nucleic acids, carbohydrates etc.). Being based on first
principles of thermodynamics, AUC is considered a ‘gold standard’ method for
determination of weight, hydrodynamic, and thermodynamic properties of biological
molecules. The AUC is nondestructive and does not rely on sample interaction with a
matrix. Although AUC is not a high throughput technique, multiple parameters can be
obtained in a single experiment. Some current practical AUC applications include
examination of sample purity, analysis of associating systems, detection of conformational
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changes, and ligand binding studies. Ongoing improvement of algorithms for AUC data
analysis further increases experimental resolution, thus the list above is expected to expand.
The behavior of a macromolecule in a centrifugal field is affected by its weight,
size, and shape. This sedimentation behavior is observed in AUC through a distribution of
analyte concentration in the centrifugal cell. Such observation is made possible by
introducing an optical system into a centrifuge. The common optical systems in modern
analytical ultracentrifuges are based either on interference, absorbance, or fluorescence.
The schematic representation of an Optima XL-A (Beckman Coulter) analytical
ultracentrifuge equipped with absorbance optics is shown in Fig. 9.
A double sector centerpiece allows loading of sample and reference solution into
two separate sector-shaped cells. This shape for the cells minimizes the convective
disturbances resulting from collision with the wall of analyte molecules traveling along
radial lines in the centrifugal field. The centerpiece is placed into the rotor and during
centrifugation, a light source is briefly fired as the cells pass the detector, while a moving
slit directs the absorbance scanning at different radial positions of the cell. Multiple scans
acquired in an AUC experiment provide information on the molecular redistribution of the
absorbing analyte during the course of the experiment. The high degree of optical precision
and detector sophistication makes scanning through the entire length of the cell at ultrahigh
(dozens of thousands revolutions per minute) centrifugation speed possible. That precision
also applies to the control of rotor temperature, which is aided by evacuation of the
centrifugation chamber to avoid warming of the fast spinning rotor due to friction with air.
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Fig. 9. Schematic of the Beckman Optima XL-A ultracentrifuge. Adapted from www.beckmancoulter.com.
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In the centrifugal field, a macromolecule (i.g., protein) is acted upon by the
centrifugal (Fc) force and two opposing forces, frictional (Ff), and buoyant (Fb). The Fc is
proportional to the mass of the macromolecule and the acceleration (reviewed in (97)):
𝐹𝑐 = 𝑚𝜔2 𝑟 =

𝑀 2
𝜔 𝑟
𝑁

where m is the mass of a molecule, M the molar mass of the solute, N Avogadro’s number,
r the distance of the macromolecule from the axis of rotation, and ω the rotor angular
velocity. As the macromolecule accelerates in the direction of the centrifugal force, the
solvent must flow around causing an increasing resistance to acceleration of the
macromolecule. One component of this resistance is the frictional force. The frictional
force depends on the velocity, size, and shape of the macromolecule:
Ff = −f V
where V is the velocity and f the frictional coefficient of the macromolecule that represents
its size and shape. The second component of solvent resistance to the macromolecule
acceleration under the centrifugal force is the buoyant force Fb, which is equal to the weight
of displaced solvent:
Fb = −mo ω2 r
mo = m ῡ ρ
where mo is the mass of the displaced solvent, m the mass of the macromolecule, ῡ the
partial specific volume of the solute (0.73 ml/g for most proteins), ρ the density of the
solvent.
The three forces come into balance very quickly, acceleration is lost, and hence, the
macromolecule sediments with a constant velocity. The velocity of the macromolecule per
unit gravitational acceleration is the sedimentation coefficient, s, defined in the Svedberg
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equation:
𝑀(1 − ῡρ) 𝑀𝐷(1 − ῡρ)
𝑉
=
= 2 =𝑠
𝑁𝑓
𝑅𝑇
𝜔 𝑟
where V is the radial velocity of the macromolecule, R the gas constant, T the absolute
temperature, D the diffusion coefficient. By inspecting the Svedberg equation, one may
easily see the direct dependence of s on the molar mass of the solute (which is corrected
for the buoyancy in the equation) and inverse dependence on the frictional coefficient of
the macromolecule. The sedimentation coefficient is expressed in Svedberg units (1 S =
10−13 sec).

Sedimentation velocity AUC of proteins
A sedimentation velocity (SV) AUC experiment primarily seeks to measure the
sedimentation coefficient of a protein molecule. An absorbance scan at each time point
during centrifugation yields a distribution of the concentration of species as a function of
radial position in the cell (Fig. 10A). At the beginning of experiment, the concentration is
uniform throughout the centrifugal cell. As the protein molecules sediment, they deplete
from a meniscus region, and a moving boundary forms. The radial position of this boundary
versus time (Fig. 10B) is the velocity of sedimentation, from which the sedimentation
coefficient may be calculated using the Svedberg equation. It may be noted that the plateau
concentration decreases over time due to radial dilution in sector-shaped cells. In addition,
as the macromolecules sediment and concentration increases toward the bottom of the cell,
the process of diffusion opposing the sedimentation intensifies, causing the boundary to
spread as indicated by the decreasing incline of the concentration distribution curve. In
principle, a higher angular velocity of the rotor would (and does in an SV experiment)
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Fig. 10. Schematic of a sedimentation velocity AUC experiment. (A) Distribution of the analyte
concentration during sedimentation at a single time point. (B) A series of absorbance scans taken at different
time points represents moving boundary. X denotes boundary midpoint. The velocity of sedimentation is the
radial position of this midpoint as function of time.

facilitate the sedimentation process resulting a sharper boundary and, ultimately, in better
precision for the sedimentation coefficient measurement. However, valuable information
concerning diffusion properties may be extracted from the rate of boundary spread. Thus,
it is possible to calculate s and D (diffusion coefficient, measured in Ficks, 1F = 10−6
cm2/sec) from a single SV experiment. These two values then can be used to determine the
weight and frictional coefficient of the protein molecule. For comparison of the
experimental values obtained under different conditions (buffer composition, temperature),
s and D can be corrected to a standard state of water at 20 °C, indicated by a subscript 20,w:
𝑠20,𝑤 = 𝑠𝑜𝑏𝑠 ×

𝜂𝑇,𝑏𝑢𝑓𝑓𝑒𝑟
(1 − ῡ𝜌20,𝑤 )
×
(1 − ῡ𝜌𝑇,𝑏𝑢𝑓𝑓𝑒𝑟 )
𝜂𝑇,𝑤

𝐷20,𝑤 = 𝐷𝑜𝑏𝑠 ×

𝜂𝑇,𝑏𝑢𝑓𝑓𝑒𝑟 293.1
𝜂20,𝑤
𝑇
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where η is the viscosity of buffer and T is the absolute temperature at which the experiment
is conducted.
Such analysis of the moving boundary works well for a single highly homogeneous
protein solute. It is also possible to analyze several sedimenting species, provided that their
sedimentation properties differ enough to produce distinct boundaries. More often, the
extent of those differences along with thermodynamic nonidealities do not allow
observation of distinct boundaries. Modern computational analysis (reviewed in (98,99)),
however, is capable of modeling experimental data points with the underlying transport
equation (Lamm equation):
𝑑𝑐 1 𝑑
𝑑𝑐
=
[𝑟𝐷 − 𝑠𝜔2 𝑟 2 𝑐]
𝑑𝑡 𝑟 𝑑𝑟
𝑑𝑟
where c is the weight concentration of the solute at radial distance r at time point t.
The boundary spreading from differential migration and from diffusion is different,
providing a basis for deconvolution of multiple sedimenting species. Direct boundary
modeling, such as the c(s)-model in the Sedfit software developed by P. Schuck (Fig. 11),
takes advantage of all experimental data points (often on the order of 105 in a single
experiment). For each s-value, a molar mass M(s) is calculated using partial specific
volume (0.73 ml/g for proteins), the measured buffer density and viscosity, and an estimate
for frictional coefficient f/f0 as a fitting parameter. The M(s) and s are then used to estimate
the diffusion coefficient D. Finally, the s and D values are used to numerically solve the
Lamm equation. A distribution of the Lamm equation solutions is then used to model the
sedimentation boundary:
𝑎𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 (𝑟, 𝑡) = ∫ 𝑐(𝑠)𝐿(𝑠, 𝐷(𝑠), 𝑟, 𝑡)𝑑𝑠 + 𝑛𝑜𝑖𝑠𝑒(𝑟, 𝑡)
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Fig. 11. Direct boundary modeling of sedimentation velocity data in the program Sedfit. Top panel depicts
multiple absorbance scans (single points in inset) collected during the AUC experiment. The software models
the sedimentation boundary (solid lines in the inset) using solutions of the Lamm equation. The quality of
modeling can be assessed from the residuals (middle panel). Bottom panel depicts the distribution of
sedimenting species as a function of sedimentation coefficient.

where a is the measured optical signal as function of radial position and time, and
L(s,D(s),r,t) is the individual Lamm equation solution. The correct weight average f/f0 is
determined iteratively by nonlinear regression (the starting value is usually 1.2, common
for many globular proteins), thus further optimizing the fit. The resulting size distribution
appears as a set of c(s) peaks, for each sedimenting species, scaled to reflect their relative
loading concentrations. A peak s-value represents the weight average sedimentation
coefficient, while the peak width is determined by the extent of f/f0 deviation, thus reflecting
diffusion properties of the species. The goodness of the fit is estimated by residuals of the
fit. The c(s) model resolves well the sedimentation coefficients of monomer, dimer, etc. It
is possible to convert c(s) into a c(M) distribution. The resulting estimate for the molar
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mass is usually within 5-10% of the correct value since this estimation is more sensitive to
the f/f0 factor than is the sedimentation coefficient.

Sedimentation equilibrium AUC
As the macromolecules sediment and concentrate at the bottom of the cell, the
process of diffusion opposes the sedimentation (reviewed in (97)). While in an SV AUC
experiment, the rotor speed (commonly 50,000 rpm) is adjusted so that sedimentation
dominates diffusion, sedimentation equilibrium (SE) experiment is conducted at a lower
rotor speed (usually ≤20,000 rpm). Given sufficient time, the two opposing processes
approach equilibrium in all parts of the solution column, and at that point the concentration
of solute increases exponentially towards the bottom. Such concentration gradient is a
function of the molar mass:
𝑙𝑛𝐶 =

𝜔2 𝑀(1 − ῡρ)𝑟 2
2𝑅𝑇

where C is the concentration, ω the rotor angular velocity, M the molar mass, ῡ the analyte
partial specific volume, ρ the density of solvent, r the radial position, R the gas constant, T
the absolute temperature.
In a graphical representation, a plot of lnC versus r2 takes a linear shape (Fig. 12)
for a single species whose molar mass can be derived from the slope (or directly from the
above equation). For multiple species, such as self-associating protein systems, the plot
‘curves’ upwards (Fig. 12B), and the slope of the tangent line at any point of that plot
represents the average molar mass of the species with a corresponding radial position in a
centrifugal cell at equilibrium.
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Fig. 12. Graphical analysis of sedimentation equilibrium data. Typical plots are presented for concentration
distribution at equilibrium for single (A) and multiple (B) species.

In the case of a monomer-dimer equilibrium, at each point r of the cell, the weight
average molar mass of species Mwr is defined:
𝑀𝑤𝑟 =

𝐶𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑀 + 𝐶𝑑𝑖𝑚𝑒𝑟 2𝑀
= 𝑓𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑀 + 𝑓𝑑𝑖𝑚𝑒𝑟 2𝑀
𝐶𝑚𝑜𝑛𝑜𝑚𝑒𝑟 + 𝐶𝑑𝑖𝑚𝑒𝑟

where M is the molar mass of a monomer, f is the fraction of monomer or dimer. Since
fdimer = 1 – fM, the fraction of monomer can be expressed as
𝑓𝑚𝑜𝑛𝑜𝑚𝑒𝑟 = 2 −

𝑀𝑤𝑟
𝑀

Thus, the concentration of monomer and dimer at each point of the cell can be calculated
along with the association constant Ka:
𝐾𝑎 =

𝐶𝑑𝑖𝑚𝑒𝑟
[𝐶𝑚𝑜𝑛𝑜𝑚𝑒𝑟 ]2

As with the SV experiments, modern software such as Sedphat (by P. Schuck) fits
experimental data to an exponential model, and the measured signal as a function of radial
position, a(r) is defined:
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𝑀𝑛 (1 − ῡ𝑛 𝜌)𝜔2 2
(𝑟 − 𝑟0 2 )] + 𝛿
𝑎(𝑟) = ∑ 𝑐𝑛,0 𝜀𝑛 𝑑 𝑒𝑥𝑝 [
2𝑅𝑇
𝑛

(adapted from (98))
where the summation is over all species n; cn,0 is the molar concentration of the species at
a reference position r0, ε is the molar extinction coefficient, d is the optical path, δ is the
baseline offset. As a result of the fit, weight average molar mass can be determined. For a
self-associating system, the association constant is introduced, and the above equation
takes the form:
𝑛𝑀1 (1 − ῡ𝜌)𝜔2 2
(𝑟 − 𝑟0 2 )] + 𝛿
𝑎(𝑟) = ∑ 𝑛𝜀1 𝑑𝐾𝑛 (𝑐1,0 ) 𝑒𝑥𝑝 [
2𝑅𝑇
𝑛

𝑛

where the subscript 1 denotes the monomer, and K1 = 1 (adapted from (98)).

It is necessary to note that such analysis is
very sensitive to noisy exponentials. For this reason,
the analysis is typically performed as a global
nonlinear regression fit of SE data obtained from a
combination of different loading concentrations and
rotor speeds (Fig. 13) to a selected model (monomerdimer equilibrium in this case). The goodness of the
Fig. 13. Analysis of sedimentation
equilibrium data obtained at different
rotor speeds (different colors) in the
program Sedphat. Single points
represent experimental data, the lines
represent theoretic fits (top panel).
Bottom panel depicts residuals of the
fit.

fit is often determined statistically using MonteCarlo noise simulations.
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Scanning electron microscopy
Scanning electron microscopy (SEM) is a technique for surface topography
imaging. Over the past few decades, the SEM instrumentation has been significantly
improved. Modern scanning electron microscopes are user-friendly and provide high
resolution images at great magnifications with little aberrations. Being once an exclusive
tool of material science, SEM has now become an attractive approach for ultrastructural
examination of biological objects.
Ultrahigh resolution SEM imaging is achieved by utilizing a focused electron beam
that is rastered from left to right and top to bottom to scan the specimen surface. The
distribution of incident beam electrons in the specimen constitutes the interaction volume
(Reviewed in (100), Fig. 14) whose spatial dimensions depend on specimen characteristics
as well as the energy of the probe beam. Upon interaction with the beam, the specimen
emits electrons, and based on the beam coordinates and the energy of emitted electrons, a
rastered pattern of grayscale values (SEM image) is generated.
Interaction of the probe beam electrons (primary electrons) with the electric field
of the atomic nuclei in a specimen results in elastic electron scattering, so called back
scattering. The energy retained by the backscattered electrons is inversely proportional to
the number of scattering events that primary electrons undergo before they ‘escape’ from
the specimen and reach the detector, and ranges from 50 eV to nearly incident beam energy.
Interestingly, the degree of backscattered emission depends on the elemental composition
of the specimen. Atoms with lower atomic number deflect electrons at smaller angles, and
the electrons experience multiple elastic collisions and greater energy loss preceding their
escape from the specimen. By contrast, higher atomic number nuclei deflect the electrons
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at larger angles, and fewer collision events are required to leave the specimen. The emitted
backscattered electrons possess higher energies and can travel from relatively far below
the surface before they

Fig. 14. Simplified representation of the interaction volume. BSE – backscattered electrons, SE – secondary
electrons. Adapted from (100).

escape the specimen. In principle, the detection of emitted backscattered electrons can be
used for specimen imaging. However, the linear dimensions of interaction volume at the
escape depths of backscattered electrons (Fig. 14) are much wider than the cross-section of
the probe beam. Such wider lateral dimension from which the signal can be generated
results in lower scanning resolution. Thereby, this detection method is rarely used for
topographic imaging. The depth of backscattering analysis is instead taken advantage of in
examination of elemental distribution within the specimen.
Another type of interaction, inelastic collision, occurs when the primary beam
electrons ionize specimen atoms causing them to expel secondary electrons. These
secondary electrons possess low, <50 eV energies, and hence, can only be emitted from
the very surface layer of a specimen. Electron scattering is negligible in that layer, and
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therefore secondary electron detection provides the most resolution for topographic
imaging.

Principal schematic of a scanning electron microscope
Every SEM instrument has a beam generating system and a detection system. The
electron beam forming system of an SEM instrument is typically regarded as a column
(Fig. 15). The electron source (gun) is located at the top of that column. In a thermionic
gun, free electrons are generated by emission from a tungsten filament at high (2700 K)
temperature. A field-emission gun utilizes an effect of high electric field applied to a metal
surface. The electron beam generated by a field-emission gun is much narrower and thus
provides better imaging resolution than the thermionic beam. The electron beam from the
gun passes between the condenser and objective ‘lenses’, which represent coil-wound
electric wires that create an electron-repulsive magnetic field converging and accelerating
the beam. Scanning coils mediate beam rastering by changing the intensity of electron
repulsive field in different directions. Irradiation of the specimen with the beam causes
emission of electrons. Those electrons hit a scintillator-coated detector thus generating
light. The light is directed to a photomultiplier tube, where it is converted to an electrical
signal. Electrons absorbed by the specimen are diverted to the ground by the metal
specimen stage.
A controlled electron beam can only be created and function as a specimen probe
under high vacuum conditions. Such conditions protect the gun filament from air oxidation
and create a dust-free environment for proper function of the electron optics. In addition,
the vacuum eliminates gas molecules and water vapors that would create an obstacle
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preventing electrons from reaching the specimen. Usually a system of two pumps
(mechanical ‘roughing’ pump and turbo-molecular pump) maintains pressure at 10−6−10−5
Torr inside the instrument.

Fig. 15. Principal schematic of a scanning electron microscope. BSE – backscattered electrons, SE –
secondary electrons

Special considerations in preparation of biological samples for SEM
A major property shared by all biological specimens is the high water content.
While low vacuum variable pressure SEM systems are available to study hydrated samples
with little to no desiccation, they provide relatively low resolution thus limiting
magnification at which imaging can be performed. In order to resolve the ultrastructural
topography of a biological specimen, this specimen must be an electron conductive dry
solid (reviewed in (101)). The main consideration taken in preparation of the biological
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SEM sample is the preservation of its structure as faithfully as possible to the native state.
In particular, drying of the biological samples subjects them to a tensile stress resulting in
inward shrinking and collapse. To avoid such structural damage, samples undergo fixation
prior to drying. The fixation is usually achieved by crosslinking of proteins with
glutaraldehyde, a homobifunctional reagent bridging two amines such as lysine side chains
that are in close proximity. In addition, when necessary, osmium tetroxide is used for
preservation of lipid structures.
Approaches to sample desiccation include freeze-drying, critical point drying, and
air-drying. Freeze-drying is essentially a sublimation technique: the sample is immersed in
liquid nitrogen followed by vacuum drying at low temperature. Such a ‘one-step’ technique
is convenient for preparation of clean, debri-free samples. The two other methods require
prior sample dehydration. This dehydration is commonly performed by stepwise
immersion of the specimen into solutions with an increasing concentration of ethanol,
accompanied by gradual dilution and ultimate elimination of water from the specimen.
Although laborious, such passing of the sample through a series of solutions provides an
additional washing benefit.
The principle behind critical point drying is that by increasing the pressure and the
temperature of a wet sample, it is possible to achieve the critical point of the liquid at which
the phase boundary between liquid and gaseous states is eliminated. The alcohol in the
dehydrated sample is substituted for acetone, and then in a special apparatus, the acetone
is exchanged with liquid CO2. The sharp temperature increase in the critical point drier
causes transition of the liquid CO2 into the gas thus drying the sample.
For air-drying, the ethanol in the sample is replaced with hexamethyldisilazane
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(HMDS). HMDS is a highly volatile organic solvent that creates very little surface tension
upon evaporation. Although HMDS is a highly toxic compound, the HMDS-drying does
not require access to specialized equipment or liquid gases, and thus can be performed in
a standard laboratory equipped with a ventilation cabinet.
The final stage in preparation of many biological objects for SEM analysis ensures
their electron conductivity. As mentioned in the section above, the primary beam electrons
absorbed by an electron-conductive specimen are diverted to the ground by a metal sample
stage. Characterized by low electron conductivity, organic specimens are not able to
transmit the absorbed electrons onto the stage. With ongoing electron irradiation, a
negative charge is accumulated at the organic surface, causing deflection of the electron
probe and resulting in image distortion and potentially in specimen damage. To address
this issue, a thin conductive layer of metal is applied onto the sample using a sputter coater.
Briefly, the sample is placed into an evacuated chamber, which is then filled with a carrier
gas such as argon at a very low pressure. A high voltage is applied to ionize the carrier gas,
and the resulting plasma ejects target material (e.g. a gold/palladium mixture) and sputters
a thin metal alloy on the sample. Other metals used for coating include platinum, silver,
chromium, iridium, and osmium. Depending on the sample dimensions and adhesive
properties, application of additional conductive materials, such as sticky carbon or copper
tape, may be necessary for more efficient coupling of the sample with the stage.
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CHAPTER 3
RECOMBINANT EXPRESSION OF FXIIIA IN ESCHERICHIA COLI
AND SITE-DIRECTED MUTAGENESIS

Introduction
Protein research requires a substantial quantity of material. Although a number of
proteins are commercially available, they do not always come at a low price. Furthermore,
characterization of a protein often involves site-directed amino acid substitutions,
extensive at times, for better understanding the structure and function relationship of that
protein. For these, and multiple other reasons, a researcher greatly benefits from
independent, in-house production of the protein of interest.
Early biochemical studies were performed using FXIII purified from plasma and
platelets. The plasma FXIII A2B2 concentration is 14−28 mg/L (corresponding to 86−172
nM of the A-subunits) while platelets contain 46−82 fg of FXIIIA2 per platelet (given the
mean platelet volume of 9 fL, 61−110 µM FXIIIA) (102-104). There is no doubt that
purification of human FXIII demanded enormous amounts of source material and was a
laborious process, with inevitably decreasing yields of the target protein after each
purification step. A 25% prevalence of the FXIIIA V34L polymorphism, mentioned in the
introductory chapter, only added to the complexity of biochemical characterization of
blood-derived FXIII.
In 1990, Bishop and coworkers reported expression and purification of human
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FXIIIA from Saccharomyces cerevisiae (105). The amount of FXIIIA obtained upon
cytosolic yeast expression was about 50 mg per L of culture. For ease of purification, the
Bishop group ligated a signal sequence to the FXIIIA gene that would promote FXIIIA
secretion by the yeast cells into the medium. The attempt was unsuccessful, and higher
yield was achieved instead by optimizing the fermentation conditions. During the final
phase of fermentation, the level of FXIIIA reached approximately 2% of the total soluble
protein, which was lower than that typically observed for other heterologous proteins,
presumably due to toxicity of FXIIIA to the yeast cells (105). Nevertheless, the quantity of
purified protein was sufficient to crystallize FXIIIA for X-ray studies (106).
The high-yield fermentation requires specialized equipment of limited availability
and often at a commercial scale. Not all experimental techniques depend on as high a
quantity of the protein material as to warrant acquisition of such equipment. In 1994,
Greenberg and coworkers reported cloning and expression of FXIII A-chains in E. coli and
their purification (107). In their initial attempts, predominantly a 30 kDa fragment was
produced, and very little full length FXIIIA. It was concluded from N-terminal protein
sequencing that the fragment resulted from internal translation starting at M474 or M475.
Consistent with these data, a Shine-Dalgarno DNA sequence AGGA was found just
upstream of the M474 codon. Converting the AGGA to TGGT DNA resulted in increase
to the full length A-chain production without alterations to the primary protein sequence.
In addition, the Greenberg group was able to express a series of FXIIIA mutants and
characterize the functional importance of certain amino acid residues as well as structural
domains (108-111).
In 2011, Smith and coworkers further optimized small-scale E. coli production of
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FXIIIA by cloning its DNA sequence into a pGEX plasmid (112). This expression vector
contained an ampicillin resistance marker and encoded FXIIIA fused with N-terminal
glutathione-S-transferase (GST) tag for affinity purification. The vector was later used for
FXIIIA expression in the Maurer research group.
In addition to expression of WT FXIIIA, a number of experiments described in the
subsequent chapters required introduction of amino acid substitutions into FXIIIA. In
particular, residue 34 (naturally occurring valine or leucine) in the FXIIIA activation
peptide has been shown to affect rates of FXIIIA activation by thrombin. Kinetic studies
employing synthetic activation peptide fragments with different amino acid residues X34
(90-96) provided valuable information on how these substitutions are accommodated by
thrombin and predicted that FXIIIA V34X substitutions may have different effects on the
fibrin clot architecture. To validate this prediction experimentally, full length FXIIIA
V34X variants1 were required to examine the effect of those substitutions on the fibrin clot
architecture.

1

All available amino acid sequences of mammalian FXIIIA contain leucine at position 34. The predominant
human variant is V34, thus it is considered a wild type. Found in approximately 25% of Caucasian population,
L34 FXIIIA has been routinely referred to as a “V34L polymorphism”. Since the presence of L34 FXIIIA is
not an isolated case, and no evidence has been reported for L34 being a result of mutation in human F13A1
gene, the V34L designation is rather misleading. While V34X designation occasionally appears in the present
dissertation, it relates to FXIIIA variants obtained using site-directed mutagenesis of the template expression
vector encoding V34 FXIIIA.
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Materials and Methods
Materials
Bacteriological grade tryptone was purchased from VWR. Bacto Yeast Extract was
purchased from BD Biosciences Advanced Bioprocessing (Miami, FL). The QuikChange
II Site-directed mutagenesis kit was purchased from Stratagene. The PreScission protease
(PSP) was from GE Healthcare. At later stages of the current research project, an
expression construct encoding GST-tagged PSP was generously provided by Dr. Jeffrey
Keillor (University of Ottawa, Canada), and this protease was produced in-house. A
fluorescence-based DNA Quantification Kit was from BioRad. The Miniprep DNA
extraction kit was from QIAGEN. Bovine liver glutamate dehydrogenase and NADH were
from Roche. All other reagents were from Sigma-Aldrich (now MilliporeSigma).
Oligonucleotide DNA primers were synthesized by IDT (Coralville, IA). A βcasein derived K9 peptide (1LGPGQSKVIG10) was synthesized by New England Peptide
(Gardner, MA), stock solutions (15-30 mM) were made in deionized H2O, and accurate
concentration was determined by quantitative amino acid analysis (AAA Service
Laboratory, Damascus, OR).

Site-directed mutagenesis for obtaining protein expression constructs
A pGEX-6P-1 vector encoding FXIIIA was generously provided by Dr. Kerrie
Smith, Dr. Robert Ariёns, and Dr. Helen Philippou (University of Leeds, UK). In this
expression construct, FXIIIA DNA is inserted downstream of the GST-tag sequence, using
BamH I as 5′ and Sal I as 3′ restriction sites. The GST is separated from FXIIIA by a
sequence encoding the PSP recognition site (LEVLFQ↓GP) for cleavage of the expressed
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GST-FXIIIA fusion protein. pGEX-6P-1 also encodes β-lactamase conferring resistance to
ampicillin and related antibiotics (Fig. 16).
The DNA mutagenesis was performed using the QuikChange Site-Directed
Mutagenesis kit following the manufacturer’s instructions. 20−50 ng of the template DNA
was combined with the mutagenic primers (forward and reverse, 120−150 ng each, Table
1) in a 0.2 mL PCR tube containing reaction buffer, dNTP mix, and the Pfu Turbo DNA
polymerase. The mutagenesis reaction was performed in sixteen thermal cycles (30 sec at
95°C; 1 min at 55°C; 7 min at 68°C). Upon completion thermal cycling, the PCR samples
were briefly chilled, supplemented with the Dpn I restriction enzyme, and incubated for 1
h at 37 °C to digest parent DNA. The PCR product was then used to transform E. coli XL1 Blue supercompetent cells. Resistance to ampicillin was used as a selection marker.
To obtain concentrated DNA samples, the XL-1 Blue cells were grown at 37°C
from a single colony in 2-5 ml of LB broth containing 100 µg/mL ampicillin. Following
overnight incubation, the cells were harvested by centrifugation at 5000 g, and the plasmid
DNA was extracted using the Qiagen Miniprep Kit. DNA concentration was determined
on the Nanodrop spectrophotometer (access to this instrument was kindly provided by
Ms. Betty Nunn from the Department of Bioengineering, University of Louisville). DNA
sequencing was performed by the University of Louisville DNA Core facility.
Upon confirmation of the desired DNA substitutions, the plasmid vectors were
transformed into E. coli BL21-Gold (DE3) competent cells (Agilent Technologies), using
ampicillin resistance as a selection marker. Cells were then grown as described above for
the XL-1 Blue cells, supplemented with 25% (v/v) glycerol, and stored at −80 °C.
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Fig. 16. A pGEX-6P-1 plasmid DNA map. Colored 5′−3′arrows highlight origin of replication (yellow), lacI gene encoding lac-repressor (dark
pink), GST-encoding sequence (light pink), and ampR gene encoding β-lactamase. Restriction nuclease sites are outlined in the periphery. FXIIIA
DNA is inserted just downstream of the GST-sequence, using BamHI and SalI restriction sites.

Table 1. Primers used for PCR-based site-directed mutagenesis to obtain expression
vectors for FXIIIA variants.
FXIIIA
variant
V34L
V34F
V34W

5′ → 3′ sequences
of forward and reverse mutagenic primers
TTCAGGGCCTGGTGCCCC
GGGGGCACAGGCCCTGAA
GCTTCAGGGCTTCGTGCCCC
GGGGGCAGAAGCCCTGAAGC
CTTCAGGGCTGGGTGCCCCGG
CCGGGGCACCCAGCCCTGAAC

Recombinant protein expression Protocol I
TB medium (1.2% Tryptone, 2.4% yeast extract, 0.4% glycerol, 100 µg/ml
ampicillin; 200 mL) was inoculated with E. coli BL21-Gold (DE3) cells from the freezer
stock and grown overnight at 37 °C in a rotary shaker at 225 rpm. This starter culture was
then used to inoculate a fresh TB medium (2 L). The culture was grown at 37 °C with
shaking (225 rpm) until optical density at 600 nm (OD600) reached 0.8−1.0. At this point,
the protein expression was induced by addition of IPTG (to 1 mM) followed by 16 h
incubation at 30 °C with shaking (180 rpm). Cells were harvested by centrifugation
(5000g) at 4 °C, rinsed to remove remaining medium, and the resulting pellets were stored
at −20 °C.

Recombinant protein expression Protocol II
ZYP-0.8G non-inducing medium (113) (1% tryptone, 0.5% yeast extract, 0.8%
glucose, 50 mM KH2PO4, 50 mM Na2HPO4, 25 mM (NH4)2SO4, 1 mM MgSO4, and 100
µg/mL ampicillin; 5 mL) was inoculated with the freezer stock cells and grown overnight
at 37 °C with shaking (225 rpm). The culture was then transferred into ZYP-5052
autoinducing medium (1% tryptone, 0.5% yeast extract, 0.5% glycerol, 0.05% glucose,
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0.2% α-lactose, 50 mM KH2PO4, 50 mM Na2HPO4, 25 mM (NH4)2SO4, 1 mM MgSO4,
and 100 µg/mL ampicillin; 0.5−2.0 L). The autoinducing culture was incubated at 37°C
until the OD600 reached 0.5-1.0, followed by the incubation at the room temperature for
additional 16−24 h. The agitation was maintained at 225 rpm throughout the entire duration
of cultivation. Biomass was harvested, rinsed, and stored as described in the section above.

Recombinant protein extraction and purification
Cell pellets were thawed and resuspended in the cold (4 °C) 50−200 mL TBS (50
mM Tris Acetate pH 7.4, 150 mM NaCl). Cells were then lysed for 2 h at 4 °C in the
presence of 1 mg/mL lysozyme, 1 mM DTT, 2 µg/mL aprotinin, 1 µM pepstatin A, 10 µM
leupeptin, 4 mM benzamidine hydrochloride, 0.5 mM PMSF, 0.05% sodium deoxycholate,
0.02% Triton X-100, and 5 µg/mL DNase I. Sometimes, RNase A was also added during
the extraction process. The cell lysate was centrifuged at 22,000g at 4 °C, followed by
treatment with 1% (w/v) streptomycin sulfate to precipitate nucleic acid and additional
centrifugation. After sterilization by vacuum filtration through a 0.2 µm membrane filter,
the clarified lysate was applied onto a 1 mL GST-trap affinity column using an Akta Prime
FPLC system. The column was then excessively washed with TBS until the absorbance of
eluent at 280 nm reached a baseline. The target protein was cleaved off the GST tag by oncolumn digestion with 100−200 µg PSP for 18 h at 4 °C and eluted with TBS. The GST
was then eluted off the column with TBS containing 20 mM reduced glutathione. FXIIIA
molar concentration was determined from absorbance readings at 280 nm using
ε = 125710 M−1cm−1 for V34, L34, and F34 variants. An ε = 131210 M−1cm−1 was applied
for FXIIIA W34. These extinction coefficients were calculated from the FXIIIA amino
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acid composition using the Protparam tool (www.expasy.org). The purity of preparations
was assessed by SDS-PAGE. Protein fractions were stored at −80 °C in small (50−200 µL)
aliquots. Some protein samples were tested for DNA contamination with a Bio Rad DNA
quantification kit following manufacturer instructions.

Activity of the recombinantly expressed FXIIIA AP variants
The transglutaminase activity of FXIIIA activation peptide (AP) variants was
detected using a standard coupled spectrophotometric assay (85,114,115). FXIIIA AP
variant (final assay concentration 1 µM) was incubated for 5 min at 37 °C in 475 µL of
TBS in the presence of chromogenic assay components (6.5 mM glycine ethyl ester, 17
mM α-ketoglutaric acid, 3 mM CaCl2, 1.2 mM ADP, 220 µM NADH, 12 U/mL glutamate
dehydrogenase, 14 mg/mL BSA) and 30 nM recombinant human thrombin. The reaction
was initiated by addition of 25 µL of 10 mM glutamine donor peptide K9. FXIIIA
expressed in S. cerevisiae served as a positive activity control.

Results
Site-directed mutagenesis
The results of initial site-directed mutagenesis attempts on the FXIIIA PGEX
plasmid suggested an overall low output of the process. The efficiency of the XL-1 Blue
cells transformation with the mutagenesis PCR product was not a concern, since multiple
bacterial colonies would grow on the agar plates in the presence of ampicillin. However,
most of the resulting plasmid samples contained original DNA, and on average, only one
out of four sequenced clones carried a desired DNA substitution. Such outcome suggested

46

that the amount of template DNA in PCR reaction was too high. The results were slightly
improved by doubling the amount of Dpn I, the restriction nuclease that cleaves the
methylated parent DNA. The best efficiency of the mutagenesis, however, was achieved
by reducing the template plasmid from 50 to 20 ng and increasing the mutagenic primers
from 120 to 150 ng in reaction. These amounts provided the optimal primer to template
DNA ratio, and all isolated plasmid samples exclusively contained mutated DNA, even
while using the standard manufacturer-suggested quantity of the Dpn I. As a result, the
expression constructs were obtained for FXIIIA variants L34, F34, and W34.

Optimization of recombinant protein expression
Initially, the GST-tagged V34 FXIIIA was expressed in E. coli using a protocol
obtained from the University of Leeds collaborators (Protocol I). This method was
previously suitable for expression of fibrinogen αC fragment (233−425). Briefly, BL21Gold (DE3) cells were transformed with a pGEX plasmid encoding GST-FXIIIA fusion
protein. Protein expression was induced with IPTG, and the resulting fusion protein was
affinity-purified on a GST-trap column. FXIIIA was freed from the GST tag by digestion
with PSP and eluted off the column separately from GST.
The absorbance profile of the eluted FXIIIA protein was characterized by a distinct
peak at 260 nm (Fig. 17A), thus suggesting a contamination with nucleic acids. By contrast,
the GST fraction had the 280 nm maximum absorbance characteristic of pure protein (data
not shown). The presence of DNA in protein preparations was unexpected, since the
purification process included use of DNase and also streptomycin to precipitate the DNA.
Given the absorbance of 1.4 at 260 nm and an average DNA extinction coefficient of
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0.02 µg−1mL−1 at this wavelength, the DNA would be present at approximately 70 µg/mL
in the sample. FXIIIA protein preparation was tested using a DNA quantification kit, and

Fig. 17. Purification of FXIIIA (4 L culture) and PSP (500 mL culture) recombinantly expressed using
Protocol I. (A) An absorbance scan of FXIIIA protein fraction demonstrating a 260 nm peak. (B) Assessment
of FXIIIA protein preparations using 8% SDS-PAGE: lane 1 – molecular weight marker, lanes 2 and 3 –
bacterial lysates prior (2) and post (3) IPTG induction. The loading amount in lane 3 was adjusted to account
for differences in optical density of the bacterial cultures before and after IPTG induction. Lane 4 – clarified
bacterial lysate, lanes 5 and 6 – FXIIIA-containing eluted fractions, lane 7 – ‘GST’-fraction eluted with
glutathione. (C) Assessment of PSP protein preparations using 10% SDS-PAGE: lane 1 – clarified lysate,
lane 2 – molecular weight marker, lanes 3-7 – eluted PSP fractions.

the DNA content was below the detection limit of 10 ng/mL. Thus, it was likely that the
contaminating nucleic acid was RNA (a much appreciated proposal from Dr. Eugene
Mueller, University of Louisville).
The FXIIIA protein bands appeared with the expected molecular weight of ~83
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kDa, however, they were barely detectable on the SDS-PAGE (Fig. 17B, lanes 5 and 6).
On the contrary, the thickness of the GST band on the gels suggested higher levels of target
protein expression (Fig. 17B, lane 7). Since no proteolytic FXIIIA fragments were detected
on the SDS-PAGE (and no putative PSP cleavage sites were found within the FXIIIA
amino acid sequence), it was concluded that FXIIIA may have precipitated upon cleavage
of the GST-tag, and only a small fraction was able to elute off the column. Greenberg and
coworkers were able to optimize a tag-free FXIIIA expression in E. coli by lowering IPTG
concentration and incubation temperature (107); however, this strategy did not improve
expression results in the current work. Notably, the PSP could readily be expressed in the
Maurer lab using IPTG induction, yielding on average 12 mg of protein from 1 L bacterial
culture (Fig. 17C).
Following advice from Dr. Jeffrey Keillor (University of Ottawa, Canada), a
different approach was implemented that involves induction of the protein expression by
α-lactose (Protocol II). As seen in Fig. 18A, the resulting FXIIIA protein had the expected
protein absorbance profile with the characteristic peak at 280 nm. The bands of the purified
FXIIIA on the gel (Fig. 18B, lanes 4 and 5) indicated >80% homogeneity and were much
thicker that those observed after initial expression attempts using IPTG, and this time, were
of comparable intensity with the GST bands (lanes 6 and 7). The yield of FXIIIA AP
variants was on average 0.4 mg per 1 L of the autoinducing bacterial culture.
This autoinduction protocol was also implemented for expression of the PSP (Fig.
17C, approximately 40 mg yield per 1 L of culture). Compared to IPTG-induction, the
autoinduction method resulted in four-fold increase of the PSP protein yield. This yield is
underestimated since, as can be seen in Fig. 18C, the PSP amount in the cell lysate was so
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Fig. 17. Purification of FXIIIA (4 L culture) and PSP (250 mL culture) recombinantly expressed using
Protocol II. (A) An absorbance scan of FXIIIA protein fraction demonstrating a 280 nm peak. (B) Assessment
of FXIIIA protein preparations using 8% SDS-PAGE: lane 1 – molecular weight marker, lanes 2 – clarified
lysate, lane 3 – column flow-through upon lysate load, lanes 4 and 5 – FXIIIA fractions, lanes 6 and 7 –
glutathione-eluted fractions. (C) Assessment of PSP protein preparations using 10% SDS-PAGE: lane 1 –
molecular weight marker, lane 2 – clarified lysate, lane 3 – column flow-through upon lysate load, lanes 4-6
– PSP fractions.

high that it exceeded the binding capacity of a 1 mL GST-trap column employed for
purification, and this excess protein was not retained on the column (lane 3). The observed
minor impurities would not create obstacles, since the PSP preparation was used in
considerable (~1:20) dilution for the current research.
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Verification of activity of FXIIIA AP variants
Unlike eukaryotic expression hosts, the intracellular environment of the E. coli
strain used in this work is reducing. Such a difference could result in altered folding and
diminished activity of the eukaryotic protein FXIIIA recombinantly expressed in E. coli.
Besides, after cleavage of the GST-FXIIIA fusion protein by PSP, the resulting FXIIIA
‘extra’ N-terminal residues GPLGSAAM. Although the presence of those residues was not
expected to affect FXIIIA conformation, the transglutaminase activity of FXIIIA variants
expressed in E. coli had to be verified. FXIIIA activity was studied using a coupled
ammonia release assay. Briefly, during the transamidation reaction FXIIIA incorporates a
primary amine glycine ethyl ester (GEE) into a glutamine-containing K9-peptide with the
release of ammonia. Glutamate dehydrogenase utilizes this ammonia along with NADH to
convert α-ketoglutarate to glutamate, accompanied by a sigmoidal decrease in absorbance
at 340 nm (Fig. 19A).
Since the thrombin-mediated cleavage rates are different for the FXIIIA AP
variants, a difference in generated activity would be expected. However, as seen in
Fig. 19B, FXIIIA AP variants demonstrated comparable activity levels. The basis for such
observation is not fully understood. As a possible explanation, in the coupled assay, the
steep decrease of NADH is preceded by a lag-phase during which ammonia accumulates
to the level necessary to saturate glutamate dehydrogenase. The presence of this lag-phase,
along with ongoing activation by thrombin, could mask the effect of the different APcleavage rates. More importantly, activity of the E. coli-expressed FXIIIA was comparable
to that of the control, yeast-expressed protein, thus indicating no significant perturbations
to the native FXIIIA structure.
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Fig. 19. Coupled transglutaminase activity assay. (A) A schematic of the assay. GEE – glycine ethyl ester,
αKG – α-ketoglutarate, Glu – glutamate. (B) Activity of recombinantly expressed FXIIIA AP variants.
Activity of yeast-expressed FXIIIA is provided for comparison.

Discussion
Recombinant protein expression and purification in the current project were first
attempted on the WT (V34) FXIIIA. Protein synthesis in E. coli with IPTG-induction
proved not to be optimal for the expression of FXIIIA and resulted in very low protein
contaminated with nucleic acid. To date, multiple researchers have reported complications
in FXIIIA expression using IPTG induction (107,113,116). In some cases, such as
described by the Greenberg group, lowering IPTG concentration resulted in overall
increased FXIIIA production in E. coli. Implementation of a similar approach, however,
did not improve FXIIIA expression in the present study, likely due to the use of a different
bacterial expression strain.
The E. coli host strain BL21-Gold (DE3) provides high recombinant protein
expression levels. The lysogenized DE3 in this strain carries the gene of T7 RNA
polymerase under the control of an inducible lacUV5 promoter. Upon addition of the
inducer, the lacUV5 promoter is derepressed, and the T7 RNA polymerase is expressed.
52

This RNA polymerase then transcribes target protein DNA from the plasmid expression
vector. Even low basal generation of the T7 RNA polymerase can result in expression of
some target proteins without induction. To avoid such unintended expression, the target
gene in the pGEX plasmid is under control of the tac promoter.
Being derivatives of the E. coli lac promoter, both lacUV5 and tac promotors direct
mRNA synthesis upon induction with the lactose analog IPTG. Enhanced inducibility of
these promotors provides high levels of the target DNA transcription, which is ultimately
supposed to result in high protein expression levels. However, tryptone, a major component
of the bacterial growth media, is often contaminated with lactose (113,116). Even trace
amounts of lactose in the medium may induce the lac-derived promotors. Aggravated by
the absence of a natural catabolite repressor such as glucose in standard media, the DNA
transcription and protein synthesis are initiated at early stages of cultivation, when the
temperature is maintained relatively high. The fast buildup of polypeptide at such high
temperature often results in a failure of orthologous proteins to adopt native conformation,
and this issue may be especially relevant to the current research. As mentioned in Chapter
1, FXIIIA has a particular four-domain fold. In addition, there are three cis-peptide bonds
present in the FXIIIA molecule, and the energetically unfavorable cis-isomerization has
been reported to be a rate limiting step in protein folding (117,118). Adding to the
complexity, such misfolding may have resulted in an impaired ability of FXIIIA to form a
correct dimer interface.
Besides the desperately low yields, a prominent feature of FXIIIA preparations
obtained using the IPTG induction protocol employed in this work was nucleic acid
contamination. Since DNA could not be detected in the preparations of FXIIIA, it was the
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RNA that may have co-purified with the target protein, but no published reports describe
the specific interaction of FXIIIA with RNA. However, given exhaustive washing steps
(over 50 column volumes) during FXIIIA purification process, a specific RNA binding to
the GST-FXIIIA fusion protein immobilized on the affinity column remained a threatening
possibility.
Experimental investigation of RNA binding to the GST-FXIIIA fusion protein is
beyond the scope of the current project, and instead the following speculation may be
offered. It is well known that unfolded proteins bind to the 50S subunit of the prokaryotic
ribosome, and in a recent report, Pathak et al. (119) demonstrated that the presence of an
unfolded protein in above stoichiometric amounts, promotes dissociation of ribosome
subunits, thereby reducing the fold-assisting function of the ribosome. As suggested above,
at the relatively high incubation temperature, the FXIIIA polypeptide is assembled faster
than it folds into the native conformation. This unfolded FXIIIA may thus have caused the
dissociation of E. coli ribosomes. Such dissociated ribosomes are susceptible to
degradation by cellular ribonucleases (119). Whether the actual ribosome degradation has
or has not taken place in the initial ‘IPTG expression’ efforts, it is possible that some
ribosomal RNA remained bound with the fusion protein on the column despite excessive
washing steps. Two current research observations indicate RNA association with the
FXIIIA portion of that protein. First, nucleic acid contamination was detected in the
samples of FXIIIA cleaved off the GST tag, and no such contamination was observed in
the GST-containing fractions. Second, two other GST-tagged proteins (PSP and fibrinogen
αC (233−425)) could readily be expressed in the Maurer lab using conventional IPTG
induction protocol, and both purified proteins were consistently nucleic acid-free.
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Instead of IPTG, the alternative autoinduction approach (113,116) to protein
expression relies on the use of a natural inducer of the lac promotor, α-lactose, in
conjunction with a catabolite repressor, glucose, in the bacterial growth media. As a
preferable carbohydrate substrate, glucose prevents transport of lactose into the cells and
hence, limits premature induction of the lac-related promoters, thus allowing the bacterial
culture to reach a certain degree of growth without overexpressing the target protein. Once
glucose is depleted from the medium, the cells switch to α-lactose utilization,
synchronously inducing target protein synthesis. Lowering the temperature below 30 °C at
this stage allows the target protein to fold ‘correctly’, ultimately increasing the yield of the
preparation. Indeed, implementation of the autoinduction protocol immediately resulted in
an increase of FXIIIA preparation quality.
Overall, a series of catalytically competent FXIIIA AP variants were expressed,
and the success of the current expression protocol is attributed to a more efficient control
of expression induction. That is, no induction is believed to occur in early stages of the
bacterial growth. Increased agitation (225 versus 180 rpm) provides better aeration of the
bacterial culture. In addition, lower temperature regime (room temperature 21−26 °C
versus 30 °C) aids in slowing the synthesis of the target polypeptide allowing it to adopt a
more native-like fold.
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CHAPTER 4
PROBING OLIGOMERIC STATES OF FXIIIA IN SOLUTION

Introduction
Plasma FXIII is found mostly as a heterotetramer of two catalytic A-subunits, and
two carrier B-subunits (A2B2), and ~1% as an A2-homodimer (120). The intracellular form,
for example in platelets, is observed exclusively as A2 (3). Both plasma and cellular FXIII
oligomers are stabilized by non-covalent inter-subunit interactions.
The A-subunit of FXIII (FXIIIA) is a transglutaminase (protein glutamine:amine
γ-glutamyltransferase) that is expressed as an inactive zymogen form (1). Two different
activation paths are currently considered for plasma- and intracellular FXIII. In a final stage
of blood coagulation, thrombin cleaves the N-terminal 4 kDa activation peptides on the Asubunits of plasma FXIII A2B2. Then in the presence of low mM Ca2+, the B-subunits
dissociate from the A-subunits exposing catalytically active transglutaminase (61). In
contrast, intracellular FXIIIA2 is thought to undergo non-proteolytic activation by Ca2+
(62-64). In vitro, FXIIIA2 can be activated by thrombin in essentially the same manner as
plasma FXIII A2B2, but without involvement of the B-subunits. In addition, the
intracellular nonproteolytic activation has been routinely simulated by the presence of nonphysiologically high (>50 mM) Ca2+ (82). Ca2+ has been demonstrated to be crucial for
transglutaminase activity, whereas other divalent cations are much less effective
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(Ca2+>Sr2+>Ba2+>Mg2+) (65). Furthermore, the binding of Ca2+ stabilizes FXIIIA
preventing its degradation by proteases (121).
Although both active sites in FXIIIA2 are exposed upon activation by thrombin,
previous inhibition studies (14,73,82) revealed that only one mole of radiolabeled
iodoacetamide (IAA) was incorporated per two moles of thrombin-activated A-subunits
(half-of-the-sites reactivity), thus negative cooperativity was proposed for the catalytic
action of FXIIIA. Interestingly, no large differences between the zymogen and thrombinactivated forms were observed in early X-ray crystal studies (69,122). However, with a
FXIIIA-catalyzed reaction where two polypeptide chains are cross-linked, significant
rearrangements in the enzyme would be required to bind substrate and to release the
product. Indeed, solution-based hydrogen-deuterium exchange and chemical modification
experiments indicated conformational alterations with opening of the FXIIIA dimer
interface upon activation (84-86). Consistent with those conclusions, non-proteolytically
activated FXIIIA that had been covalently inhibited was later crystallized with an exposed
active site and proposed to be monomeric (72). In the present work, the oligomeric state of
the A-subunits of FXIII is addressed in a solution environment.
Single amino acid substitutions in FXIIIA are believed to have the potential to
disrupt dimer formation. A few candidates had been identified in patients with severe FXIII
deficiency: R260L, R260C, Y283C, and G562R. Activation peptide substitution R11Q was
computationally predicted to impair A2 dimer formation. Most of those mutants were
unstable in eukaryotic expression systems (74-79). Recombinant expression in E. coli
along with affinity purification could be more feasible for obtaining mutant proteins,
however, this approach had not been attempted before.
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Materials and Methods
Materials
Recombinant FXIIIA expressed in S. cerevisiae was a generous gift from the late
Dr. Paul Bishop (Zymogenetics, Seattle, WA). A stock solution of FXIIIA (40 µM) was
made in deionized water. Concentration was determined from the absorbance at 280 nm
using ε = 125710 M−1cm−1 (calculated using Protparam tool, www.expasy.org), and
aliquots were stored at −80 °C. Molar concentration of FXIIIA in this work refers to the
A-subunits, as opposed to A2-dimers. Bovine thrombin was purchased from SigmaAldrich. Thrombin inhibitor d-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK)
was purchased from Haematologic Technologies (Essex Junction, VT). FXIIIA inhibitor
peptide K9-DON (85) was synthesized by Zedira (Darmstadt, Germany), and a stock
solution (500 µM) was made in dimethyl sulfoxide (DMSO). All other reagents were from
Sigma-Aldrich.

FXIIIA sample preparation for AUC
All samples were prepared in a final volume of 500 µL for sedimentation velocity
and 130 µL for sedimentation equilibrium experiments. To study nonproteolytic activation
of FXIIIA, 2−6 µM zymogen was incubated in borate buffer (20 mM boric acid, 150 mM
NaCl, pH 7.8) in the presence of 100 mM CaCl2 at 37 °C for 30 min. As a negative control
for a divalent metal cation, 100 mM MgCl2 was employed. For proteolytic activation,
FXIIIA (2−6 µM) was treated with 3.5 NIH U/mL bovine thrombin in the borate buffer
containing 4 mM CaCl2 for 30 min at 37 °C, following by addition of 760 nM thrombin
inhibitor PPACK.
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For inhibition studies, FXIIIA (2 μM) activated by thrombin in the borate buffer
with 4 mM CaCl2 was inhibited with five-fold molar excess of alkylating agent
iodoacetamide (IAA) or five-fold molar excess of covalent inhibitor peptide K9-DON.
Samples of inhibited FXIIIA were supplemented with 5% DMSO.
Control samples of zymogen FXIIIA (2 µM) were made in PBS (10 mM sodium
phosphate, 150 mM NaCl, pH 7.4 (105)) or in borate buffer.

AUC
The oligomerization and hydrodynamic properties of zymogen as well as activated
FXIIIA were studied by analytical ultracentrifugation. Samples were subjected to
centrifugation within 2 h of preparation.
Sedimentation velocity experiments were carried out in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge at 20 °C and 50,000 rpm in standard twosector cells. Buffer density was determined on a Mettler/Paar Calculating Density Meter
DMA 55A at 20 °C and viscosity was measured using an Anton Parr AMVn Automated
Microviscosimeter

at

20 °C.

Data

were

analyzed

with

the

program

Sedfit

(www.analyticalultracentrifugation.com) using the continuous c(s) distribution model. The
partial specific volume of FXIIIA was calculated from the amino acid composition
(0.734 mL/g) using the Protparam tool (www.expasy.org). Frictional ratios were calculated
by Sedfit assuming no bound water. Experimental sedimentation coefficients were
converted to s20,w using the corrections based on the measured density and viscosity.
Analytical runs were performed with at least two independent samples for each condition
examined.
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Sedimentation equilibrium experiments were carried out in standard two-sector
cells using 150 µL of buffer in the reference sector and 130 µL of sample in the sample
sector. Three different rotor speeds were used and equilibrium was confirmed by observing
the identical distribution of 280 nm absorbance in three successive scans at 2 h intervals
for each rotor speed. Data were analyzed using the program Sedphat. Global analysis was
carried out using the monomer-dimer self-association model. Error analysis was performed
using the Monte-Carlo error analysis feature of Sedphat with 1000 iterations.

Intrinsic tryptophan fluorescence measurements
Fluorescent spectra were collected using a Perkin Elmer LS55 spectrofluorimeter.
FXIIIA samples were prepared in the same manner as for the AUC. Prior to the
measurements, each sample (500 µL) was transferred into a 4.0 ml quartz cuvette and
diluted with corresponding buffer to a final volume of 2.0 ml (thus resulting in final FXIIIA
concentration of 500 nM). Samples were excited at 280 nm, and emission spectra at 300400 nm were recorded. Fluorescence measurements were conducted with two independent
samples for each condition studied.

Native polyacrylamide gel electrophoresis (nPAGE)
Samples of FXIIIA were prepared similarly to the AUC studies but in smaller
volumes (20−100 µL). Samples were then supplemented with a loading buffer (0.5 M Tris,
pH 6.8; 20% glycerol, 0.01% w/v bromophenol blue) in a 2:1 sample:buffer ratio.
Electrophoretic separation was conducted at room temperature in a Tris-Glycine running
buffer without SDS using 4% stacking and 7.5% resolving gels. During electrophoresis,
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the temperature of the running buffer did not elevate above 28 °C. Gels were stained with
Coomassie Blue. At least three independent samples were studied for each condition, with
essentially the same results.

Size exclusion chromatography (SEC)
SEC was conducted using a 10 × 300 mm Superdex 75 analytical column (GE
Healthcare) on an Akta FPLC (GE Healthcare). The column was calibrated with gel
filtration standard from BioRad containing proteins of known Stokes radii (RS): bovine γglobulin (150 kDa, RS = 5.1 nm), chicken ovalbumin (43 kDa, RS = 2.8 nm), and equine
myoglobin (17 kDa, RS = 1.9 nm). Dextran Blue and vitamin B12 were used to determine
the void column volume (V0) and the total volume (Vt), respectively. The BioRad standard
protein mixture was separated in borate buffer. Samples of zymogen FXIIIA as well as
100 mM Ca2+ and 100 mM Mg2+ -treated FXIIIA were prepared as described for the
sedimentation velocity AUC. Due to possible precipitation of the thrombin-activated
FXIIIA on the analytical column, this form was not subjected to SEC analysis.
For each run, a 100 µL aliquot of 2 µM protein sample was applied to the column
that had been pre-equilibrated with corresponding buffer. All protein separations were
carried out at 0.5 ml/min, room temperature. Protein elution was monitored by absorbance
at 280 nm. The peak elution volume (Ve) of each protein was converted to a partition
coefficient (σ) using the equation
σ=

(𝑉𝑒 − 𝑉0 )
(𝑉𝑡 − 𝑉0 )

where Vt is the total column volume and V0 is the void volume.
An inverse error function (erf -1) was calculated for (1- σ) (123) of each calibration
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standard and plotted against their Stokes radii. This calibration “curve” was then used to
determine RS for different forms of FXIIIA.
Site-directed mutagenesis, recombinant protein expression and purification
Experimental manipulations for obtaining FXIIIA mutants with proposed impaired
dimerization were conducted as described in Chapter 3. The primer pairs used for
mutagenesis PCR are listed in the Table 2, along with brief descriptions of the mutants.

Table 2. Primers used for PCR-based site-directed mutagenesis to obtain expression
vectors for FXIIIA mutants.
FXIIIA
mutant

R11Q

R260L

R260C

Y283C

G562R

5′ → 3′ sequences
of forward and reverse
mutagenic primers

Description
The activation peptide residue R11 forms a salt
bridge with D343 of the opposite subunit. The
R11Q substitution was computationally
predicted to impair dimer formation, however, it
could not be expressed in eukaryotic cells (79).
R260 is located at the dimer interface. A
substitution
may
result
in
impaired
dimerization. R260L was expressed in COScells and underwent rapid intracellular
degradation (74).
Molecular modeling of R260C predicted
impaired dimerization. Expression in BHKcells resulted in rapid degradation. R260C
expressed in yeast, subjected to gel filtration,
and was concluded to be a monomer (75-77).
Y283 is located in the catalytic core of FXIIIA.
Y283C was expressed in MEG-cells at very low
level. Gel filtration suggested monomeric state
of the mutant, and impaired binding with Bsubunits was observed (78). Remarkably,
residue Y283 is conserved among the
transglutaminase family with the majority of
members existing as monomers state.
G562 is located in β-barrel 1. G562R mutant
was expressed in MEG-cells, and was
concluded to exist as a monomer from gel
filtration analysis (75,78).
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CTTTGGAGGCCAGAGAGCAGTTC
GAACTGCTCTCTGGCCTCCAAGG

CAAAGTCAGCCTGGTGGGGTC
GACCCCACCAGGCTGACTTTG

CAAAGTCAGCTGCGTGGGGTC
GACCCCACGCAGCTGACTTTG

GGGACAATATCTGTGCCTATGGCGTC
GACGCCATAGGCACAGATATTGTCCC

CTTCTACACCCGCGTCCCGAAGG
CCTTCGGGACGCGGGTGTAGAAG

Results
Activated FXIIIA species experience significant conformational rearrangement compared
to the zymogen form
In an attempt to probe FXIIIA for possible conformational rearrangements in
solution upon activation, a series of intrinsic tryptophan fluorescence measurements was
performed (Fig. 20A). To activate FXIIIA proteolytically (by cleavage of the activation
peptide), the zymogen was incubated with thrombin in the presence of 4 mM Ca2+. Nonproteolytic activation was achieved in the presence of 100 mM Ca2+. An overall
fluorescence decrease (17–18%) was observed for activated FXIIIA forms relative to the
zymogen, suggesting an increase in polarity of the environment surrounding some of the
tryptophan residues in the FXIIIA molecule. Thus, these tryptophan residues became more
solvent-exposed, indicating conformational rearrangements in the A2-homodimer. As a
control, FXIIIA was also treated with 100 mM Mg2+, and only a slight effect on intrinsic
fluorescence of the protein (5% decrease) was detected. While activation by thrombin was
optimal at physiological temperature (37 °C), high mM Ca-activation proceeded even at
room temperature (21−26 °C), and the fluorescence decrease could be monitored
continuously in the non-thermostated instrument. Under conditions of both proteolytic and
nonproteolytic activation, fluorescence reached minimum values at 30 min.
To further assess possible dissociation of FXIIIA upon activation, a series of nondenaturing polyacrylamide gel electrophoresis (nPAGE) experiments was conducted. A
significant change in FXIIIA electrophoretic mobility was visible upon activation by
thrombin (Fig. 20B, lane 2) and by 100 mM Ca2+ (Fig. 20B, lane 3). However, these
conditions caused the protein to spread along a migration path (especially in thrombin-

63

Fig. 20. (A) Fluorescence emission spectra of FXIIIA under different conditions. Control zymogen FXIIIA
is shown in red; (B) nPAGE of FXIIIA: lane 1 – zymogen FXIIIA; lane 2 – FXIIIA activated by thrombin
in the presence of 4 mM CaCl2; lane 3 – FXIIIA activated with 100 mM CaCl2; lane 4 – FXIII treated with
100 mM MgCl2; (C) SEC elution profiles of FXIIIA under different conditions (left): zymogen in borate
buffer (red), FXIIIA in the presence of 100 mM CaCl2 (green), and FXIIIA in the presence of 100 mM
MgCl2 (dark blue). Arrows indicate peak elution volumes (Ve) of the calibration standards (i –
thyroglobulin, 670 kDa, Ve = 7.80 ml; ii – bovine γ-globulin, 158 kDa, Ve = 8.40 ml; iii – chicken
ovalbumin, 43 kDa, Ve = 9.87 ml; iv – equine myoglobin, 17 kDa, Ve = 11.89 ml); calculation of RS (right)
for FXIIIA forms based on their partition coefficients (σ): erf -1 (1-σ) values were plotted versus RS for the
calibration standards (i – 8.6 nm, ii – 5.1 nm, iii –2.8 nm, iv –1.9 nm). The RS-values were calculated for
FXIIIA samples (circles): 5.0 nm for zymogen, 4.8 nm for FXIIIA treated with 100 mM MgCl2, and 3.5
nm for FXIIIA in the presence of 100 mM CaCl2.
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activated FXIIIA) yielding no well-defined bands on the gel. By contrast, the migration of
FXIIIA treated with 100 mM Mg2+ (Fig. 20B, lane 4) was identical to that of the zymogen
form (Fig. 20B, lane 1).
Finally, FXIIIA was analyzed by size exclusion chromatography (SEC, Fig. 20C).
Both zymogen and 100 mM Mg2+-treated FXIIIA had similar elution profiles. Their Stokes
radii were determined to be 5.0 nm and 4.8 nm, respectively. In the presence of 100
mM Ca2+, FXIIIA eluted after the zymogen form, and its Stokes radius was 3.5 nm. These
observations were consistent with the possibility of dissociation of FXIII A2-homodimer
upon non-proteolytic activation.

FXIIIA2 dissociates into monomers upon activation
Although fluorescence measurements, nPAGE, and SEC results indicated
significant perturbations in FXIIIA upon activation, the oligomerization states of the
enzyme forms remained inconclusive. In contrast, analytical ultracentrifugation (AUC)
provided distinct resolution of the FXIIIA species. Representative results of sedimentation
velocity analyses are summarized in Table 3 and Fig. 21. The dimeric state of FXIIIA
zymogen in solution was confirmed (Fig. 21, trace i). The sedimentation coefficient of
~7.9 S was consistent with the molecular weight of ~160 kDa. A frictional ratio of ~1.3
indicated a slightly asymmetric molecule. In the presence of 100 mM Mg2+, 90% of the
protein existed in the dimeric form (Fig. 21, trace iii). A profound change in sedimentation
properties was observed in the presence of 100 mM Ca2+ (Fig. 21, trace ii). This nonproteolytically activated FXIIIA migrated uniformly with a sedimentation coefficient of
~4.8 S, consistent with the molecular weight ~80 kDa, thus indicating a monomeric state.
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Table 3. Hydrodynamic parameters of FXIIIA.

Sample

s20,w, S

Frictional ratio

FXIIIA zymogen

7.91

1.32

7.85

1.35

4.83

1.38

4.80

1.31

7.93

1.35

7.73

1.35

4.57

1.53

4.70

1.37

FXIIIA with 100 mM Ca2+
FXIIIA with 100 mM Mg2+
FXIIIA thrombin-activated in presence of 4 mM Ca2+

Sedimentation coefficients (in Svedberg units, S) and frictional ratios were obtained by analyzing
sedimentation velocity data using the Sedfit software. Observed s-values were corrected to s20,w. For each
experimental condition, data are presented for two independently made samples.

Fig. 21. Representative sedimentation velocity profiles of FXIIIA. (i) – FXIIIA zymogen in the borate
buffer; (ii) – FXIIIA incubated in the presence of 100 mM CaCl2; (iii) – FXIIIA incubated in the presence
of 100 mM MgCl2; (iv) – FXIIIA cleaved by thrombin in the presence of 4 mM CaCl 2. For all conditions,
loading concentration of FXIIIA was 2 µM. c(s) is the concentration distribution as a function of s20,w.
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A more detailed analysis of the non-proteolytically activated FXIIIA oligomeric state is
presented in Chapter 5.
AUC of thrombin-activated FXIIIA revealed a monomer with a sedimentation
coefficient of ~4.6 S (Fig. 21, trace iv). Although no significant differences could be seen
between the frictional ratios of thrombin-cleaved FXIIIA compared to non-proteolytically
activated enzyme (Table 3), the broader peak of the thrombin-activated form (Fig. 21, trace
iv) was suggestive of a more flexible conformation of FXIIIA after activation peptide
cleavage. In addition, as previously observed (73,124), thrombin-activated FXIIIA tends
to aggregate over the course of a few hours, causing its low abundance in solution and thus
making it difficult to analyze by both SEC and AUC. Whereas non-denaturing treatment
with sodium deoxycholate or dithiothreitol did not resolve this issue, the addition of 5%
DMSO was found to facilitate solubility of the active FXIIIA, without causing dissociation
of zymogen FXIIIA2 or affecting the enzyme catalytic activity (data not shown).

Quantitative analysis of FXIII A-subunits interactions
To assess inter-subunit interactions in FXIIIA quantitatively, a series of
sedimentation equilibrium AUC experiments was conducted. Representative distribution
profiles obtained for the zymogen and activated forms at three different rotor speeds are
presented in Fig. 22. Global fitting of experimental data to a monomer-dimer equilibrium
model yielded apparent dissociation constants (KD) for dimerization of FXIIIA. As
expected, interactions of the A-subunits in the zymogen form were relatively tight (KD = 8
nM). Much higher KD-values (indicating weaker interactions) were calculated for activated
FXIIIA: 90 mM for non-proteolytically activated and 220 mM for thrombin-activated
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FXIIIA. Obtained at much lower centrifugal force than that used in the sedimentation
velocity experiments, sedimentation equilibrium results provide critical support that
activated FXIIIA is likely to exist in monomeric form at physiological concentrations.

Fig. 22. Analysis of monomer-dimer equilibrium of FXIIIA forms. Sedimentation equilibrium profiles are
presented for single loading concentration: (A) 2 µM zymogen FXIIIA; (B) 4µM FXIIIA in the presence
of 100 mM CaCl2; (C) 4 µM FXIIIA activated by thrombin in the presence of 4 mM CaCl2. Experimental
data (open symbols) obtained at each rotor speed (denoted on the figure panels) were fitted to a monomerdimer equilibrium model (solid lines). Residuals are provided below the fitted data. Apparent KD-values
were 8 nM for the zymogen FXIIIA, 90 mM for FXIIIA in the presence of 100 mM CaCl 2, and 220 mM
for the thrombin-activated FXIIIA. Global molecular weight values were 158,424 Da for zymogen, 86,801
for CaCl2-activated FXIIIA and 77,025 for thrombin-activated FXIIIA. Monte-Carlo error analysis
indicated an average error for zymogen (A) of ±30 Da in molecular weight and ±0.03 for log KA, for
CaCl2-activated FXIII (B) of ±40 Da in molecular weight and ±0.003 for log KA, and for thrombinactivated FXIII (C) of ±60 Da in molecular weight and ±0.002 for log KA.

Activated FXIIIA remains monomeric upon binding of substrate analogs
To study possible structural rearrangements in the active FXIIIA upon binding
substrate analogs, thrombin-activated enzyme was subjected to alkylation of the active site
C314 by the thiol reagent IAA. As another test candidate, a peptide inhibitor K9-DON
(1LGPG-(DON)-SLVIG10), where glutamine is replaced with its isostere 6-diazo-5-oxonorleucine (85) was used to target the FXIIIA catalytic site region. These two covalent
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FXIIIA-inhibitor adducts resemble an acyl-enzyme intermediate transiently formed during
the transglutaminase reaction. In the AUC experiments, both FXIIIA-IAA and FXIIIA-K9DON complexes appeared as monomers with no significant differences in the
sedimentation coefficient compared to thrombin-activated free enzyme (Fig. 23).

Fig. 23. Sedimentation velocity analysis of covalently inhibited FXIIIA. Structures of IAA and K9-DON
are depicted in an insert.

FXIIIA mutants with proposed impaired dimerization
Certain single amino acid substitutions were previously predicted to impair
dimerization of the zymogen FXIIIA form (74-79). To obtain solution evidence of such
impairment in the current work, the expression of these mutants was attempted in E. coli.
Following the autoinduction protocol described in Chapter 3, the GST-tagged FXIIIA
mutants were affinity purified and liberated from the GST by on-column cleavage with
PSP. The protein levels in eluted fractions were extremely low for R11Q, R260C, R260L,
and G562R as judged by the absorbance at 280 nm (Fig. 24A, left), and undetectable by
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Fig. 24. Analysis of recombinantly expressed in E. coli FXIIIA mutants with proposed impaired
dimerization of the zymogen. (A) Representative absorbance profiles of purified mutant proteins cleaved
off the GST-tag (left) and purified as fusion proteins without cleavage of the tag. (B) SDS-PAGE analysis
(8% gels) of the GST-FXIIIA mutant proteins: MW – molecular weight standard, lane 1 – clarified
bacterial lysate, lane 2 - column flow-through upon lysate load, lanes 3 and 4 – GST-FXIII containing
fractions. (C) Purified GST-FXIIIA mutant proteins were subjected to PSP-mediated cleavage of the GSTtag in microfuge tubes and analyzed by 8% SDS-PAGE: MW – molecular weight standard, lane 1 – sample
of FXIIIA mutant after cleavage the GST tag, lane 2 – sample of PSP-cleaved FXIIIA was centrifuged at
10,000 rpm, followed by resuspension of the pellet in sample loading buffer.
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the SDS-PAGE. These FXIIIA mutants were then purified without use of PSP and eluted
off column with the covalently attached GST tag. As seen from Fig. 24A (right) and
Fig. 24B, the GST-fused FXIIIA mutant proteins could be expressed in E. coli at
reasonable levels. An increased (compared to the WT FXIIIA) amount of impurities
detected by the SDS-PAGE was likely due to increased susceptibility of the mutants to
intracellular proteolytic degradation, thus suggesting significant structural perturbations.
Subsequent cleavage of the GST-tag (Fig. 24C) resulted in visible precipitation of R11Q,
R260C, R260L, and G562R FXIIIA, thus further confirming solution instability of the
mutants in the absence of the chaperoning GST tag.
Unlike the mutants described above, Y283C FXIIIA could be readily purified and
eluted off the column without the GST tag, at levels comparable to the WT FXIIIA, with
only minor impurities detected by the SDS-PAGE (Fig. 25 A, B). The nPAGE mobilities
of Y283C FXIIIA and its hetero-complex with FXIIIB (Fig. 25C, lanes 4 and 5) were
identical to those observed for the WT FXIIIA (Fig. 25C, lanes 1 and 3). The SEC elution
profile of Y283C was, again, similar to the WT FXIIIA (Fig. 25D).
Additional information about the Y283C mutant was obtained in a series of AUC
experiments (Fig. 25E). In the zymogen form, Y283C FXIIIA sedimented primarily as a
dimer, although with a slightly lower sedimentation coefficient (7.6 S) than the WT FXIIIA
(7.9 S). With WT and Y283C mutant having the same molecular weight, such a lower
sedimentation coefficient indicated an increased asymmetry of the mutant FXIIIA
molecule. A minor portion, 10% of total protein in the sample, had a sedimentation
coefficient 4.9 S consistent with being a monomer. In the presence of 100 mM Ca2+, all
protein was uniformly monomeric with the sedimentation coefficient of 4.9 S, close to the
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Fig. 25. Analysis of recombinantly expressed in E. coli FXIIIA mutant Y283C. (A) Representative
absorbance profile of the mutant protein purified and cleaved off the GST-tag. (B) SDS-PAGE analysis
(8% gel) of Y283C FXIIIA: MW – molecular weight standard, lane 1 – bacterial lysate, lane 2 – column
flow-through upon lysate load, lane 3 –Y283C protein, lane 4 –GST-containing fraction. (C) nPAGE
analysis of Y283C FXIIIA: lane 1 – control WT FXIIIA, lane 2 – control FXIIIB, lane 3 – WT FXIIIA
(excess) incubated with FXIIIB, lane 4 – Y283C FXIIIA, lane 5 –Y283C FXIIIA incubated with excess
FXIIIB. (D) SEC elution profile of zymogen Y283C FXIIIA. Arrows indicate elution volumes of WT
FXIIIA zymogen (dimer) and 100 mM CaCl2-treated FXIIIA (monomer) (E) Sedimentation velocity
profiles of Y283C FXIIIA: zymogen form (red), Y283C in the presence of 100 mM CaCL 2 (green), and
thrombin cleaved Y283C in the presence of 4 mM CaCl 2. For comparison, c(s) traces of WT FXIIIA
zymogen (dimer) and in the presence of 100 mM CaCl2 (monomer) are plotted as dashed lines.
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WT FXIIIA s-value at these conditions (4.8 S). Interestingly, thrombin cleavage of AP on
the Y283C FXIIIA resulted in a 3.9 S species. By analogy with the WT FXIIIA, such a
large difference (1 S-unit) between sedimentation coefficients of the two Y283C
monomeric forms would not be expected to result solely from proteolytic removal of a
4 kDa activation peptide. Thus, the difference originated from the more global
rearrangements present in the proteolytically cleaved Y283C FXIIIA than in the
nonproteolytically dissociated mutant.

Discussion
Oligomeric assemblies of proteins, particularly those of enzymes, attracted the
attention of investigators as soon as it was realized that such assemblies regulate protein
function (125). With continuing advances in experimental techniques and instrumentation,
the scope of protein oligomerization research has expanded significantly. It has been
estimated (126) that 60% of enzymes form oligomers. Many of these enzymes may exist
as monomers but require self-association to fulfill the catalytic function. By contrast, the
spotlight of the current project is on a protein that is inactive in its oligomeric form.
In this work, the oligomerization states of the A-subunits of FXIII were evaluated
under different solution conditions. Intrinsic tryptophan fluorescence profiles and
electrophoretic mobilities of both proteolytically and non-proteolytically activated forms
of FXIIIA were different from that of the control zymogen, suggesting significant
perturbations to the protein upon activation. However, the attempt to resolve proteolytically
and non-proteolytically activated FXIIIA using nPAGE encountered difficulties and did
not yield defined protein bands on the gels. By contrast, similar experiments with
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homologous monomeric Transglutaminase 2 demonstrated two different forms. In nPAGE
(127) as well as capillary electrophoresis (128), high mobility (compact conformation) and
low mobility (extended conformation) species were observed. These species were
correlated with the crystal structures of inactive and active enzyme, respectively.
A reasonable explanation for the current nPAGE results is that during separation in
an electric field Ca2+ ions would be migrating in the opposite direction from the negatively
charged protein, constantly “washing out” from the samples. Interestingly, the activation
of FXIIIA by high concentrations of Ca2+ was previously shown to be a reversible process:
loss of catalytic activity was observed upon removal of the Ca2+ ions from FXIIIA, and the
protein could be re-activated again by addition of Ca2+ (129). Thus, nPAGE results in the
current study indicate that presumably monomeric, activated FXIIIA might re-associate
into zymogen-like dimers or higher-order aggregates upon loss of Ca2+ ions. This
phenomenon occurred specifically in the presence of Ca2+ but not Mg2+, adding to the
evidence that Ca2+ is critical for maintaining the conformation of active FXIIIA.
SEC analysis indicated different sizes (Stokes radii) of zymogen FXIIIA and its
activated form. However, FXIIIA is not an ideal globular protein (Fig. 5, Chapter 1),
therefore caution had to be taken when correlating SEC data with molecular weights of
FXIIIA forms. By contrast, AUC provided information on the molecular weight and the
shape of the protein in solution. The results of sedimentation velocity AUC experiments
confirmed the dimeric state of zymogen FXIIIA2 and its asymmetric shape, in accord with
existing crystal structures and ultracentrifugation studies by Bishop et al. (105). FXIIIA
activated proteolytically by thrombin in the presence of low (4 mM) Ca2+ appeared as a
monomer. Compared to the non-proteolytically Ca2+-activated form, the broader
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sedimentation coefficient peak distribution of thrombin-cleaved FXIIIA could indicate its
more flexible conformation, and additional relevant experimentation is discussed in the
following dissertation chapter.
Gupta and coworkers (87) conducted molecular dynamics simulations using a
crystal structures of zymogen FXIIIA. Steered dissociation of the zymogenic dimer
occurred within 60 ns. For simulation of proteolytic activation, the activation peptides were
removed from the zymogen crystal structure, and the steered dissociation of A-subunits
required only 30 ns. Based on those time requirements, the Gupta group concluded that
proteolytic

FXIIIA

activation

causes

dissociation

of

the

A-subunits,

while

nonproteolytically activated FXIIIA was characterized as a “weak dimer”. In the current
work, solution based sedimentation equilibrium AUC provided a more apposite strategy to
characterize inter-subunit interactions of FXIIIA forms quantitatively. The apparent
dissociation constant for the zymogen FXIIIA was in the nanomolar range, whereas the
value increased into the millimolar range for both proteolytically and nonproteolytically
activated FXIIIA. To give an idea of the physiological range of FXIII concentrations in
platelets, an established reference interval for FXIII A2 is 46–82 fg/platelet (103). With the
mean platelet volume of 9 fL (104), the concentration of the A-subunits is 61–110 µM. The
plasma level of FXIII A2B2 is 14–28 mg/L (102), corresponding to 86–172 nM of the Asubunits. During a coagulation event, activated FXIII is mobilized at the clotting site and
its local concentration may exceed regular plasma levels; however, the amount would not
be expected to reach high millimolar values. Since dissociation of the B-subunits from the
A-subunits after cleavage of the activation peptide has been well documented (2,3), the
physiological presence of FXIIIB is not predicted to significantly affect post-cleavage
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rearrangements of FXIIIA in plasma. Thus, the in solution observed drastic weakening of
inter-subunit interactions in the current research supports the concept of physiological
dissociation of FXIII A-subunits upon activation.
An observation of monomeric, thrombin-activated FXIIIA is contrary to previously
reported results. Chung and coworkers (73) performed AUC of both plasma (A2B2) and
platelet (A2) FXIII using 50 mM sodium citrate buffer. A valid concern from the Chung
study is that most of the added (10 mM) Ca2+ may have been chelated by citrate. Under
their conditions, the dissociation of B2-dimer from the A2-dimer had occurred, but no
evidence for the presence of monomeric FXIIIA either in plasma or platelet-derived
enzyme was obtained, much like in the current nPAGE efforts. In the present study, no
chelating agents were used in the buffers, thus 4 mM Ca2+ present in the samples was
available for binding and stabilizing monomeric thrombin-cleaved FXIIIA (121).
In an X-ray crystal study, Yee et al. (122) reported no significant changes in
structure of FXIIIA after activation with thrombin. However, non-cleaved FXIIIA
zymogen was present in their crystallographic samples, which was described as a “minor
component” (>20%). Since thrombin-cleaved FXIIIA is prone to precipitation especially
at the high concentrations (10 mg/ml) used, the Yee group may have actually crystallized
the “minor component”, zymogen FXIIIA, instead of the thrombin-cleaved form.
Verification of the cleavage was not possible due to disordered nature of the cleavage site
in FXIIIA activation peptide.
Earlier experiments employing radiolabeled IAA (14,73,82) suggested that only
half of the possible catalytic sites underwent alkylation, thus half-of-the-sites reactivity
was postulated for the enzyme, implying its dimeric state. Upon observing active FXIIIA
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as a monomer in the present study, a possibility of re-association of the two active Asubunits upon binding an inhibitor to one of them was considered. To test this possibility,
activated FXIIIA was modified with IAA or the more substrate-like peptide K9-DON to
form covalent adducts with the active site C314 that mimic the acyl-enzyme complex. No
dimerization was observed in sedimentation velocity analyses of both inhibited FXIIIA
species. While there is no reason to dispute previous findings of the Folk (73) and Shafer
(14,82) research groups on half-of-the-sites reactivity of FXIIIA, there is an obvious need
for a detailed study of possible cooperativity in FXIIIA-mediated catalysis.
In the dimeric FXIIIA zymogen, the outer, solvent exposed parts are formed mainly
by the β-sheet structural elements that are less susceptible to proteolytic degradation, while
the more vulnerable α-helical structures are shielded within the dimer interface (Fig. 5,
Chapter 1). At the same time, the active sites in the dimeric zymogen are buried, thus
preventing premature activation and undesirable protein crosslinking. A few naturally
occurring mutants causative of severe FXIIIA deficiency (R260C, R260L, Y283C, and
G562R (75-78)) and an experimental activation peptide mutant R11Q (79) were predicted
to be unable to dimerize and thus susceptible to intracellular proteolytic degradation. In the
current work, one of those mutants, Y283C, could be successfully expressed and purified.
The Y283 residue is located rather distant from the FXIIIA dimer interface (Fig. 7, Chapter
1), and its contribution to that interface would be modest. As observed in the SEC
experiments, the Y283C substitution did not significantly affect the size of the FXIIIA
molecule. AUC results indicated a local conformational distortion affecting overall shape
of the A-subunits, but only slightly impaired dimerization of the zymogen. By contrast,
R11, R260, and G562 residues directly participate in interactions of the A-subunits, and in
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the current work, mutations of those residues resulted in solution instability of FXIIIA. The
mutants only remained soluble while still attached to the dimeric GST-tag. Collectively,
these observations suggest that the dimeric state of FXIIIA is critical for stabilization of
the zymogen form. In a physiological context, a high demand for FXIIIA in emergency of
bleeding may not be quickly satisfied by inducible synthesis and extracellular secretion of
such a large protein. Thus, a stand-by pool of FXIIIA molecules must be, and is, maintained
in plasma in a dimeric zymogen form, that is protected from premature activation and
degradation.
To summarize, current research provides experimental insight into FXIIIA
oligomeric states in solution. For the first time, homodimeric FXIII A2 was demonstrated
to dissociate as a part of the activation process, and inter-subunit interactions were
quantitatively assessed. Current findings not only contribute to understanding the structure
and function relationship in FXIIIA, but also provide a clue as to the regulation of this
transglutaminase.1

1

Some contents of this chapter are reproduced from the published manuscript: Anokhin, B.A., Stribinskis,
V., Dean, W.L., and Maurer, M.C. (2017) Activation of factor XIII is accompanied by a change in
oligomerization state. FEBS J 284, 3849-3861.
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CHAPTER 5
INVESTIGATION OF DYNAMIC AND FUNCTIONAL IMPLICATIONS
OF FXIIIA ACTIVATION PATHWAYS

Introduction
FXIIIA has been a subject of medically related research for almost a century.
Perhaps the most studied is the role of FXIIIA in crosslinking the fibrin network. As
physiological knowledge on FXIII expands, it becomes apparent that beyond serving as a
key player of the blood coagulation system, FXIIIA functions in would healing, bone tissue
dynamics, and even signaling processes (2-5,21,48,49,54,130).
FXIIIA is a transglutaminase that crosslinks protein substrates via an isopeptide
bond in a Ca2+-dependent manner. FXIIIA is expressed as an inactive zymogen and in
plasma, it circulates in a heterotetrameric complex with carrier FXIIIB (A2B2). During
blood coagulation, FXIII is activated by thrombin-mediated removal of N-terminal
activation peptides from the A-subunits followed by binding of Ca2+ and dissociation of
the B-subunits (61). The active FXIIIA then introduces covalent crosslinks between
polymerizing fibrin molecules and incorporates other proteins into the network, ultimately
increasing mechanical stability of the resulting clot and its resistance to fibrinolysis (131).
Intracellularly, such as in platelets, monocytes, and macrophages, FXIII exists as
an A2-homodimer and is thought to undergo slow nonproteolytic activation in the presence
of low available Ca2+ concentrations (62-64). In this physiological compartment, FXIIIA
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is primarily present in the cytoplasm, sometimes associated with membrane (56), and even
appears in the nucleus (9). Intracellular functions of FXIIIA include reorganization of
cytoskeletal proteins and chromatin remodeling (5). FXIIIA is also secreted by osteoblasts
into the ECM (57), where it contributes to formation of the ECM itself and remodeling of
the bone tissue (49,55,56). Although a proteolytic fragment of FXIIIA that results from
posttranslational intracellular modification has been detected in the ECM (47,57), it was
later identified as transaldolase 1 (53). With available ECM Ca2+ concentrations as high as
25–40 mM (45,132), bone ECM FXIIIA may be activated by Ca2+ without proteolysis.
Being involved in an array of intra- and extracellular events, FXIIIA has also been
implicated in associated pathological conditions such as thrombotic disease (17), arthritis
(41), etc. FXIIIA has thus become an attractive target for pharmacological intervention,
and development of therapeutic regimes effectively managing FXIIIA in its particular
physiological environments warrants an in-depth understanding of FXIIIA activation and
function in such locations. Solution studies discussed in the previous chapter revealed that
FXIII A2-homodimer dissociates into monomers as part of the activation process. Research
focused next on probing the functional implications of FXIIIA activation pathways: (i)
thrombin activation of FXIIIA in the presence of low mM Ca2+ (occurring in plasma, the
resulting active species are henceforth denoted as FXIIIA*), (ii) nonproteolytic activation
by low mM Ca2+ (intracellular activation, FXIIIA°,low), and (iii) activation in the presence
of high (≥25 mM) Ca2+ (bone ECM, FXIIIA°,high).
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Materials and Methods
Materials
Recombinant FXIIIA expressed in S. cerevisiae was a gift from the late Dr. Paul
Bishop (Zymogenetics, Seattle, WA). Bovine thrombin was purchased from SigmaAldrich. Recombinant human thrombin was generously provided by Dr. Enrico Di Cera
and Dr. Leslie Pelc (St. Louis University) Thrombin inhibitor PPACK was from
Haematologic Technologies (Essex Junction, VT). A glutamine-containing substrate
peptide K9 was synthesized by New England Peptide (Gardner, MA), stock solutions
(15−30 mM) were made in deionized H2O, and accurate concentration was determined by
quantitative amino acid analysis (AAA Service Laboratory, Damascus, OR). Fibrinogen
αC (233−425) was recombinantly expressed in E. coli using autoinduction media and
purified as described in Chapter 3. Bovine liver glutamate dehydrogenase and NADH were
from Roche. All other reagents were from Sigma-Aldrich.

FXIIIA activation for AUC experiments
For full proteolytic activation, 2 µM FXIIIA2 was incubated in borate buffer
(20 mM boric acid, pH 7.8, 150 mM NaCl) with bovine thrombin (3.5 NIH units/ml) and
4 mM CaCl2 for 30 min at 37 °C. To achieve a limited amount of proteolysis (cleavage of
approximately half of the A-subunits), the zymogen (2 µM) was incubated with 3.5 NIH
U/mL thrombin for 6 min at 28 °C. All proteolytic activation reactions were quenched with
760 nM PPACK. In addition to 4 mM CaCl2, some samples of the proteolytically activated
FXIIIA were supplemented with 100 mM MgCl2.
For nonproteolytic activation, 2 µM zymogen FXIIIA2 was incubated in the borate
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buffer containing 4–100 mM CaCl2 for 30 min–6 h at 37 °C. FXIIIA was also incubated in
the borate buffer at a lower, 4 mM CaCl2 for 30 min–96 h. To achieve better solubility of
FXIIIA at these conditions, the 4 mM Ca2+-samples were supplemented with 5% DMSO.
A detailed description of AUC experimental parameters can be found in Chapter 4.
Briefly, samples of activated FXIIIA were subjected to sedimentation velocity AUC at
20 °C and 50,000 rpm. Data were analyzed using the program Sedfit and experimental
sedimentation coefficients were corrected based on the measured density and viscosity of
the buffer, thus allowing direct comparison of results obtained with different experimental
conditions. Analytical runs were performed with at least two independent samples for each
condition examined.

Coupled ammonia release activity assay
Transglutaminase activity of FXIIIA was determined using a standard coupled
spectrophotometric assay as described in Chapter 3. The only alteration was maintaining
the CaCl2 concentration at 4 mM for the thrombin-activated FXIIIA and 100 mM for the
non-proteolytically activated enzyme. Activity measurements were performed in
triplicates.

Monodansylcadaverine (MDC) crosslinking activity assay
In order to compare activities of proteolytically and nonproteolytically activated
FXIIIA, a series of MDC crosslinking assays was performed. For proteolytic activation,
1 µM FXIIIA was incubated in TBS (50 mM Tris Acetate, pH 7.4, 150 mM NaCl) with
30 nM recombinant human thrombin and 4 mM CaCl2 for 30 min at 37 °C, followed by
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addition of 760 nM thrombin inhibitor PPACK. Nonproteolytic activation was achieved by
30 min incubation of 1 µM FXIIIA in TBS in the presence of 100 mM CaCl2.
Recombinantly expressed fibrinogen αC (233–425) was used as a glutamine donor
(Q-substrate). αC (2–40 µM final) was preincubated with a lysine mimic MDC (Ksubstrate, 1 mM final, from a 20 mM stock solution in methanol) in TBS containing CaCl2
(4 – 100 mM final concentration) for 5 min at 37°C. The crosslinking reaction was initiated
by addition of activated FXIIIA (final concentration 100 nM). Aliquots were taken at 1 –
7 min and quenched by addition of reducing sample loading buffer, followed by 3 min of
boiling. Samples were resolved using SDS-PAGE on 15% gels. Prior to Coomassie blue
staining, the gels were photographed under UV light. This assay was performed at least
twice for each condition studied.

Direct continuous chromogenic activity assay
In this assay adapted from de Macedo et al. (133), FXIIIA incorporated
chromogenic K-substrate N,N-dimethyl-1,4-phenylenediamine (DMPDA) into a Qsubstrate K9-peptide (1LGPGQSKVIG10). The reaction progress was monitored by an
increase in absorbance at 278 nm resulting from an anilide functionality in the crosslinked
product. Nonproteolytic and proteolytic activation was performed as described for the
MDC assay, except that FXIIIA was 1–4 µM in the activation mix. K9-peptide (46–
1386 µM final) was preincubated with DMPDA (700 µM final, from a 100 mM stock
solution in methanol) in the borate buffer with 4 or 100 mM of CaCl2 for 5 min at 37 °C.
The reaction was initiated by addition of activated FXIIIA (final concentration
0.25−1.0 µM). Reaction velocities were determined over the initial part of the absorbance
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curve. An ε = 8940 M−1cm−1 (133) was applied to convert absorbance to µM of crosslinked
product. Velocities in µM product/min were fitted to the Michaelis-Menten equation as a
function of the K9 concentrations using Kaleidagraph software (Synergy).

Results
Dynamics of proteolytic activation of FXIIIA
In the previous chapter, FXIII A2 was demonstrated to dissociate into monomers
upon activation by thrombin. Under the conditions employed, FXIIIA was fully cleaved by
thrombin within 30 min. Previously published kinetic studies by Hornyak et al. (14)
suggested that only one activation peptide has to be cleaved on the FXIIIA2 dimer to expose
the active sites in both subunits in the presence of Ca2+. To assess the oligomerization state
of this “single-cleaved” FXIIIA*, activation conditions were adjusted so that
approximately half of the A-subunits were cleaved by thrombin (Fig. 26A). A series of
samples was prepared, and some of them were supplemented with 5% DMSO to promote
solubility of the monomeric FXIIIA* species. Representative AUC results for these “halfcleaved” samples are depicted on Fig. 26C. From a quantitative analysis of sedimentation
velocity data of one of the samples (without DMSO), 48% of the protein appeared as a
monomer, 42% was a dimer, and 10% formed a large aggregate. Another sample was
supplemented with 5% DMSO, and no aggregation was observed yielding 62% monomer
and 38% dimer. Assuming random cleavage by thrombin, the resulting distribution of
species in these samples (Fig. 26B) would be ~ 25% A2 (non-cleaved zymogen) : 50% AʹA
(“single-cleaved”) : 25% Aʹ (“double-cleaved”). Hence, the “double-cleaved” species
would constitute ~25% of monomers in the samples. Current observation of 48% (with no
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DMSO) and 62% (in the presence of 5% DMSO) monomeric protein can be accounted for
by assuming dissociation of a major portion of the “single-cleaved” FXIIIA dimers.

Fig. 26. Analysis of monomer-dimer distribution of FXIIIA partially activated by thrombin in the presence
of 4 mM CaCl2. (A) SDS-PAGE (8% gel) monitoring cleavage of FXIIIA by thrombin. (B) Theoretic
distribution of non-cleaved and cleaved species in the “half-cleaved” samples of FXIIIA. Question marks
denote unknown oligomerization state of the “single-cleaved” species. (C) Representative c(s) distribution
in the “half-cleaved” samples with (dashed line) and without (solid line) addition of 5% DMSO.
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Dynamics of nonproteolytic activation of FXIIIA
Similar to the proteolytic activation by thrombin, FXIIIA activation in the presence
of 100 mM Ca2+ led to a complete dissociation of the A-subunits within 30 min (Chapter
4). For a more detailed assessment of FXIIIA non-proteolytic activation dynamics, the
protein was treated for 30 min in the presence of different concentrations of Ca2+. The
samples were then subjected to AUC. The resultant sedimentation velocity data were used
to quantitate the amount of FXIIIA monomers depending on the concentration of Ca2+
(Fig. 27). As expected, increasing Ca2+ concentrations resulted in a greater amount of
monomers.

Fig. 27. FXIIIA dissociation as a function of Ca2+ concentration. All samples were incubated at 37°C for
30 min.

There was now an interest in examining the FXIIIA nonproteolytic activation
process at lower, more physiological Ca2+ concentrations. FXIIIA was incubated in the
presence of 4 mM Ca2+ for 30 min – 96 h, and all samples were subjected to AUC in the
same run. The amount of protein in solution was assessed at the start of an AUC
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experiment. Unexpectedly, progressive precipitation was observed in these samples of
FXIIIA°,low, very similar to the solution behavior of the thrombin-activated FXIIIA*. In
previous experiments, addition of 5% DMSO promoted solubility of FXIIIA* over the
course of a few hours. However, low mM Ca2+ activation required longer incubation
periods to obtain detectable results, and even addition of DMSO did not aid in full
solubility of FXIIIA°,low. As seen in Fig. 28A, approximately 60% of the protein was
insoluble by 96 h of incubation with 4 mM Ca2+. By contrast, in a control sample of
zymogen FXIIIA (in the absence of Ca2+), only 9% of the protein was lost to aggregation
at that incubation time (data not shown).
The plot in Fig. 28C (open circles) represents the amount of monomeric FXIIIA as
a fraction of soluble protein in each sample. The most observed dissociation of the Asubunits, ~ 65%, was observed after 72 h incubation. This amount is likely underestimated,
since in the presence of low Ca2+ concentrations it is the monomeric FXIIIA that is prone
to precipitation, as seen in experiments with FXIIIA*. Such activation of FXIIIA may
proceed intracellularly, although much slower than observed in the presence of 4 mM Ca2+,
since Ca2+ is actually maintained at 20−200 nM level in most resting cells (134) and can
be elevated to ~1 mM in activated platelets (62,63).
In order to mimic activation conditions of bone tissue ECM, FXIIIA was incubated
in the presence of higher, 25 mM Ca2+ for 30 min – 6h (Fig. 28 B and C, filled circles).
The dissociation of the dimeric zymogen under these conditions occurred significantly
faster than at 4 mM Ca2+ (80% at 6 h of incubation) and, analogous to activation by 100
mM Ca2+, no precipitation of these FXIII°,high species was observed. Thus, current results
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Fig. 28. Dynamics of FXIIIA dissociation in the presence of 4 (FXIIIA°,low, open circles) and 25
(FXIIIA°,high, filled circles) mM CaCl2. (A) Assessment of soluble protein amount (fraction of total) in the
samples of FXIIIA°,low, (B) Representative c(s) distributions of FXIIIA°,high activated in the presence of
25 mM CaCl2 for 30 min (dotted line), 3 h (dashed line), and 6 h (solid line). (C) Amount (fraction of
soluble) of monomeric protein in the samples of FXIIIA°,low (open circles) and FXIIIA°,high (filled circles).

indicate that nonproteolytic activation of FXIIIA may readily be achieved at much lower
Ca2+ concentrations than previously thought (50 mM). In physiological conditions, such a
mechanism is certainly expected to proceed slower than proteolytic activation by thrombin,
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given that cleavage of a single activation peptide on the dimeric zymogen is often sufficient
to activate both A-subunits.

Solution properties of FXIIIA species in different activation conditions
AUC results discussed in the previous chapter suggested differences in the
conformational flexibility of FXIIIA* (activated by thrombin in the presence of 4 mM
Ca2+) and FXIIIA°,high (activated in the presence of 100 mM Ca2+). There was now an
interest in directly comparing the solution behavior of these two active FXIIIA forms. In
the current investigation, a necessary control for a divalent cation-mediated ionic strength
effect was provided by supplementing FXIIIA* samples with 100 mM Mg2+. Unlike Ca2+,
this divalent cation does not efficiently support dissociation or activity of FXIII A-subunits.
In addition, to eliminate possible differences in sample handling between separate
analytical runs, all sample conditions were subjected to AUC at the same time.
The resulting sedimentation coefficient distributions are presented in Fig. 29. In the
presence of 100 mM Ca2+ (trace i), we observed a tall narrow peak, approximately 1 S unit
in width. Significant precipitation occurred in FXIIIA* samples during centrifugation, and
the sedimentation distribution peak was much broader, approximately 2 S (trace ii). In the
presence of 4 mM Ca2+ and 100 mM Mg2+ (trace iii), the FXIIIA* sedimentation peak was
also broad (2 S). Sedimentation coefficients represent the velocity of particle sedimentation
(in the present case, FXIIIA molecules) in a centrifugal field. Apart from the physical
characteristics of a solution, which are accounted for in data analysis, the sedimentation
coefficient ultimately depends on the weight and shape of those particles. Thus, in samples
of monomeric FXIIIA, it is the diversity of shapes (conformations) that constitutes the
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sedimentation distribution. The broad sedimentation distribution peak indicates that
FXIIIA* is more conformationally heterogeneous in solution than FXIIIA°,high, and this
heterogeneity is retained in the presence of 100 mM Mg2+. This observation suggests a
specific effect of Ca2+ on FXIIIA conformation rather than a simple increase in ionic
strength due to the higher concentration of divalent cation.

Fig. 29. Comparison of c(s)-distributions for activated FXIIIA: (i) FXIIIA°,high, (ii) FXIIIA*, (iii) same as
(ii) with addition of 100 mM MgCl2. For each condition, two independent samples were prepared. All six
samples were analyzed in the same centrifugation run.

Catalytic activities of proteolytically and non-proteolytically activated FXIIIA
The transglutaminase activity of FXIIIA under different activation conditions was
first compared using a standard coupled spectrophotometric assay (85,114,115). As a brief
description of the assay, FXIIIA incorporates a primary amine glycine ethyl ester (GEE)
into a glutamine-containing K9-peptide with the release of ammonia. Glutamate
dehydrogenase utilizes this ammonia along with NADH to convert α-ketoglutarate to
glutamate, accompanied by a sigmoidal decrease in absorbance at 340 nm (Fig. 30A). The
reaction velocity is determined as a slope at the steepest part of the absorbance curve.
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Fig. 30. Coupled ammonia release assay of FXIIIA transglutaminase activity. (A) Representative
absorbance curves monitoring FXIIIA-mediated ammonia release followed by oxidation of NADH (left):
(i) – FXIIIA* fully cleaved by thrombin, (ii) – same as (i), with addition of 5% DMSO, (iii) – FXIIIA*
sample with ~50% of the A-subunits cleaved by thrombin, (iv) – FXIIIA°,high (100 mM CaCl2).
Transglutaminase activity of FXIIIA is presented by the rate of ammonia-dependent NADH oxidation
(right). Measurements were performed in triplicates for each condition, and values are presented as mean
± SD. (B) Control experiments (with no FXIIIA) monitoring NADH oxidation by GDH in the presence of
different CaCl2 concentrations. Reactions were initiated by addition of NH 4Cl.

In previous experiments, 5% DMSO facilitated solubility of thrombin-cleaved
FXIIIA*, however this co-solvent could affect conformation and hence, catalytic activity
of the enzyme. As seen from Fig. 30A (ii), addition of 5% DMSO did not affect
transglutaminase activity of the FXIIIA*. The activity of samples with half of the A-
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subunits cleaved by thrombin (Fig. 30A, iii) was ~3/4 of that observed with the fullycleaved FXIIIA*, consistent with previous reports (14,105). Surprisingly, enzyme fully
dissociated in the presence of 100 mM Ca2+ (FXIIIA°,high) yielded much lower activity
(Fig. 30A, iv) than fully activated FXIIIA*. Additional control experiments, however,
revealed that high mM Ca2+ had an inhibitory effect on the activity of the coupling enzyme
glutamate dehydrogenase (GDH). As seen from Fig. 30B, the GDH activity in the presence
of 100 mM is ~3.5 fold less than at 4 mM Ca2+, a difference identical to that observed with
FXIIIA* (4 mM Ca2+) and FXIII°,high (100 mM Ca2+).

For a more reliable assessment of the possible catalytic differences between
FXIIIA* and FXIIIA°,high, a direct spectrophotometric transglutaminase assay, developed
by de Macedo with coworkers (133) was adapted. With the K9 peptide still serving as a
glutamine substrate, the chromogenic DMPDA was used as the second, amine substrate.
Unlike the coupled assay based on detection of released ammonia, the transglutaminase
reaction in this method is monitored by appearance of crosslinked product that absorbs at
278 nm (Fig. 31A). More important, this assay is not sensitive to high Ca2+ concentrations.
At first glance, the downward curvature of the Lineweaver-Burk plots, such as the
one in Fig. 31B (left), suggested that initial reaction velocities could not saturate, in other
words, they did not approach the Vmax. Such a response of activated FXIIIA forms to
increasing K9-peptide concentrations would be characteristic of negative cooperativity.
Noteworthy, half-of-the-sites reactivity, an extreme case of negative cooperativity, was
previously reported for irreversible covalent inhibition of FXIIIA (14,73,82). However,
since each FXIII A-subunit contains one active site, half-of-the-sites activity
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Fig. 31. DMPDA kinetic assay of FXIIIA transglutaminase activity. (A) A schematic of the assay reaction.
(B) Representative Lineweaver-Burk plots constructed using initial velocities of crosslinking reactions in
the presence of 0.5 and 1.0 µM FXIIIA*. (C) Progress curves typical for the crosslinking reactions
catalyzed by 1.0 µM FXIIIA. (D) Michaelis-Menten fits of reaction velocities measured with 1.0 µM
FXIIIA* (solid line, triangles) or FXIIIA°,high (dotted line, circles). Apparent Km and Vmax obtained from
the fits are shown in the insert. Values are presented as mean ± SD (n = 3).
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toward the substrate would only be possible for a dimeric enzyme. As demonstrated in the
current work, activated FXIIIA is a monomer. Therefore, instead of cooperative substrate
binding, the currently observed effect could result from hysteretic kinetics (135) of the
FXIIIA-catalyzed reaction. More precisely, a slow conformational rearrangement in the
enzyme molecule would limit the overall catalytic rate. Thus, the reaction velocity would
not increase anymore despite increasing substrate concentrations. Examples of such ratelimiting transitions in ‘cooperative’ enzymes include among others transient selfassociation or dissociation (135). Interestingly, at higher FXIIIA concentration, the
negative cooperativity effect disappeared, as indicated by the absence of curvature on
double-reciprocal plot (Fig. 31B, right), consistent with a possible transient dimerization
of the A-subunits during the course of the catalyzed reaction. That is, higher FXIIIA
concentration could accelerate hypothetical transient reassociation of the A-subunits, and
such reassociation would not be rate-limiting any longer.
As another explanation, the observed negative cooperativity effect could result
from limiting concentration of one of the two transglutaminase substrates. Indeed, due to
decreased water solubility, a concentrated 100 mM DMPDA stock solution was prepared
in methanol. Care then had to be taken in selection of the DMPDA concentration used in
the assay, in order not to introduce a large amount of methanol. In addition, DMPDA in
aqueous solution strongly absorbed at 220–260 nm, resulting in the ‘tale’ absorbance at the
product detection wavelength of 278 nm, and thus limiting the DMPDA amount that could
be employed in the assay without exceeding the linearity of absorbance readings. With the
above considerations, 700 µM DMPDA (0.7% (v/v) of methanol) as a final assay
concentration was found to be optimal. Since up to ~1400 µM K9 was employed in the
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assay, the DMPDA would become a limiting substrate at K9 concentrations above 700 µM.
However, as seen on Fig. 31D, the reaction velocities only approached saturation at K9
concentrations above 1 mM. In addition, inspection of the reaction progress curves
revealed the maximal product accumulation of approximately 120 µM, thus further
suggesting that reaction velocities were not simply limited by availability of DMPDA.
Interestingly, a 5 min incubation of enzyme with the DMPDA (a valuable suggestion from
Dr. Eugene Mueller) prior to addition of the K9 resulted in significant loss of FXIIIA
transglutaminase activity (data not shown). Such inactivation of the enzyme did not occur
immediately, as the initial velocities, measured over the first 20–30 sec of the reaction, still
increased with increasing K9 concentrations. Nevertheless, no affirmative conclusions
could be made regarding the presence of cooperativity in FXIIIA-mediated catalysis. In
addition, the Km and Vmax parameters obtained from the Michaelis-Menten fit are likely not
the true values, and thus only serve for functional comparison of nonproteolytically and
proteolytically activated FXIIIA forms.
Compared to FXIIIA°,high, an apparent Km for K9 peptide was almost two-fold
lower for FXIIIA*, suggesting better interaction of this enzymatic form with the glutamine
substrate. On the other hand, FXIII°,high demonstrated a stronger apparent Vmax value
suggesting that once saturated with the glutamine donor K9, FXIII°,high provides faster
substrate turnover than FXIIIA*. It is necessary to note that the higher apparent Km of the
FXIII°,high is not simply a reflection of higher achievable velocities of this form. While at
lower K9 concentrations, FXIII°,high reaction velocities were lower than those for FXIIIA*,
an opposite trend was observed at higher K9 concentrations. Even though the observed
kinetic parameters would not result in a dramatic difference between overall catalytic
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efficiencies of the two FXIIIA forms acting on a short peptide substrate, they further
corroborate proposed conformational differences between FXIIIA* and FXIIIA°,high.
Next, a series of SDS-PAGE assays was conducted to monitor FXIIIA-catalyzed
crosslinking of a lysine mimic monodansylcadaverine (MDC) to a glutamine donor
fibrinogen αC (233−425) (Fig. 32A). The dansyl moiety of MDC provides a ‘fluorescent
tag’ on the protein and once the αC band is resolved by SDS-PAGE, the crosslinking
reaction can be monitored by fluorescence of that band. αC represents a physiological
protein substrate of FXIIIA* and contains three reactive glutamines (136). While four
lysine residues are present in the αC (233−425) sequence, no competing αC-αC
conjugation, that would result in appearance of species of ≥40 kDa, was detected even at
high αC concentrations (Fig. 32B, bottom panel). At lower 2−10 µM αC concentrations,
the extent of MDC incorporation catalyzed by FXIIIA* was greater than by FXIIIA°,high
(Fig. 32B). This difference became less apparent at 20 µM and indistinguishable at the high
30−40 µM αC (Fig. 32B). Thus, the results obtained with a physiological protein αC
substrate indicate that FXIIIA* interacts with the glutamine donor more readily than does
FXIIIA°,high, further supporting observations with the short K9-peptide in the DMPDA
assay.
To examine a possible effect of the presence of 100 mM Ca2+ on the αC
conformation or MDC fluorescence, the crosslinking reaction was repeated in the presence
of lower 25 mM Ca2+ (Fig. 32C). MDC crosslinking to αC by 100 mM Ca2+-activated
FXIIIA°,high was essentially the same regardless of Ca2+ concentration in the crosslinking
reaction mix and still lower than that catalyzed by FXIIIA*.
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Fig. 32. (A) A schematic of the assay reaction (B) MDC assay of FXIIIA transglutaminase activity as
function of αC concentration. The samples of each reaction time point were loaded on 15% SDS-PAGE
side by side for FXIIIA* (triangles) and FXIIIA°,high (circles). Samples were separated on two gels: 1−4
and 5−7 min points. The gels were then aligned, transilluminated with UV, and photographed (light on
dark panels). The bottom panel depicts a Coomassie Blue-stained gel pair with no competitive αC-αC
crosslinking. (C) MDC assay of FXIIIA°,high transglutaminase activity as function of CaCl2 concentration.
The layout is the same as in part A. FXIIIA°,high (circles) was always activated in the presence of 100 mM
CaCl2. A control AUC experiment revealed that upon dilution to 25 mM CaCl 2, FXIIIA°,high remained
monomeric. Samples of FXIIIA*-catalyzed reactions (triangles) are presented for comparison.
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Discussion
Currently available anticoagulants inhibit coagulation factors upstream from
FXIIIA, sometimes resulting in coagulation deficiencies and unfortunate side effects
ranging from increased bruising to life-threatening uncontrollable bleeding with no
effective antidotes available. Being the final player of the coagulation cascade, FXIIIA has
been recognized as a promising target for novel anticoagulant agents with a prospect of
fewer side effects (17). Attempts are underway to design effective inhibitors of FXIIIA
(72,137,138). However while implementing new coagulation management regimes, it may
be desirable not to affect FXIII function in nonhemostatic events. Notably, those
nonhemostatic functions may themselves present therapeutic interest.
The previous chapter results qualitatively demonstrated dissociation of FXIII Asubunits during activation. The diversity of FXIIIA activation conditions in physiological
compartments such as blood plasma, intracellular, and bone ECM, may impart distinct
properties on the active FXIIIA forms presenting a basis for differential therapeutic
targeting of FXIIIA in those compartments. This hypothesis warranted further
investigation of the dynamic and functional implications of FXIIIA activation pathways.
As a result, research focused on comparing FXIIIA activation by thrombin in the presence
of low mM Ca2+ (occurring in plasma, FXIIIA*), nonproteolytic activation by low mM
Ca2+ (intracellular activation, FXIIIA°,low), and activation in the presence of high (≥25 mM)
Ca2+ (bone ECM, FXIIIA°,high).
Thrombin-catalyzed proteolysis results in FXIIIA activation within minutes.
Previous activity studies by Hornyak et al. (14) and Bishop et al. (105) revealed that
cleavage of a single activation peptide on dimeric FXIIIA zymogen already resulted in
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expression of full activity for both, cleaved and noncleaved A-subunits. In the present
study, samples where half of the FXIIIA subunits were cleaved by thrombin exhibited ~3/4
activity compared to the ‘fully-cleaved’ FXIIIA, in agreement with previously published
data. Intuitively, one would expect ~ 75% monomers in such a sample if all ‘singlecleaved’ species became monomers. Yet the AUC analysis revealed 62% monomeric
protein, thus indicating that some of the ‘single-cleaved’ species remained dimeric at the
concentrations and solution conditions employed in this work. In activity assays,
dissociation of these species could be promoted by the presence of substrate. These results
further confirm high efficiency of FXIIIA proteolytic activation. At the same time,
proteolytically activated FXIIIA* tends to aggregate, suggesting a relatively short lifetime
for this species.
Intracellular FXIIIA has been reported to undergo non-proteolytic activation by
Ca2+ ions (62,64). To imitate this activation pathway in the current work, FXIIIA was
treated with low 4 mM Ca2+ resulting in progressive dissociation of the zymogenic dimers.
Similar to FXIIIA* species, the aggregation propensity of FXIIIA°,low predicts its short
lifetime. Such observation is in a good agreement with a study by Muszbek et al. (62),
reporting only a small 6.5% of FXIIIA population within platelets being active. The slow
appearance of FXIIIA°,low has limited its isolation and characterization in the current study.
The poor solubility may suggest some similarity of this form with FXIIIA*. Furthermore,
equal activity of both cleaved (FXIIIA*) and noncleaved (essentially FXIIIA°,low) subunits
in the presence of low mM Ca2+ supports this proposal.
In contrast to FXIIIA* and FXIIIA°,low, activation in the presence of high (≥25 mM)
Ca2+, that may proceed in ECM of the bone tissue, did not result in aggregation of
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FXIIIA°,high species. Increased Ca2+ concentration was shown before to stabilize active
FXIIIA in solution (14), and in current AUC experiments, higher Ca2+ levels were
correlated with reduced conformational heterogeneity of FXIIIA°,high as compared to
FXIIIA*. Notably, this effect was not observed in the presence of control Mg2+. Thus, the
differences in solution behavior of FXIIIA in the presence of low and high mM Ca2+ imply
binding of different amounts of Ca2+ to FXIIIA at different ambient concentrations of this
cation. Interestingly, in the presence of low mM Ca2+, activated Y283C FXIIIA* (Chapter
4), had significantly lower sedimentation coefficient than the WT FXIIIA* under the same
conditions. Given the same molecular weight for WT and mutant, the decrease in s-value
indicated a greater hydrodynamic volume for the Y283C mutant protein molecule resulting
from conformational distortion. The presence of high mM Ca2+ resulted in identical
sedimentation properties for the mutant and WT FXIIIA, thus possibly reducing the effect
of that conformational distortion.
In enzymatic evaluations, FXIIIA* had an almost two-fold lower Km for the
glutamine substrate than had FXIIIA°,high, thus suggesting stronger interaction of FXIIIA*
with that substrate. On the other hand, FXIIIA°,high provided faster reaction turnover upon
saturation with the glutamine donor. It is well known that the transglutaminase reaction
proceeds through a ping-pong mechanism involving binding of Q (glutamine) and K
(amine) substrates (60). The possibility has been suggested of nonproductive complex
formation between K-substrate and free transglutaminase enzyme (139). However, in a
productive catalytic cycle, the K-substrate enters the reaction after the enzyme forms a
complex with the Q-substrate. Therefore, the currently observed faster turnover by
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FXIIIA°,high may be due to better interaction with the K-substrate and faster release of the
crosslinked product.
Since in the presence of low mM Ca2+ both cleaved and noncleaved FXIIIA
monomers are equally active, as indicated in previous publications (14,105) and confirmed
in the current study, the observed differences in activities of FXIIIA* and FXIIIA°,high
could not be explained by the absence or presence of the activation peptide. Another
important factor to consider is, again, the possible difference in amount of Ca2+ bound by
those two FXIIIA forms. In early work, Lewis and coworkers (140) reported that each Asubunit of plasma zymogen FXIII A2B2 binds a Ca2+ ion with KD = 100 µM. Hornyak et
al. (82) later demonstrated that another Ca2+ ion is required by each A-subunit to dissociate
from the B-subunits and to expose catalytic cysteines.
Stieler and coworkers (72) recently crystallized FXIIIA°,high with a covalently
bound Q-mimic inhibitor providing the first molecular structure of active FXIIIA. Besides
the previously observed first, zymogenic Ca2+ site (70), the Stieler research group elegantly
demonstrated the functional significance of two additional sites. In particular, development
of the 2nd Ca2+ site brought about conformational changes in the FXIIIA molecule to initiate
formation of a hydrophobic pocket for the K-substrate entrance. This site is the same as
that presumed by Hornyak (82) to promote exposure of the reactive thiol on the A-subunits.
Coordination of the 3rd Ca2+ was proposed by Stieler et al. to conclude formation of the
hydrophobic pocket and to facilitate binding of the K-substrate. Since the binding of Q and
K is sequential and the presented crystal structure resembles a covalent FXIIIA–Qsubstrate intermediate, an idea may be entertained that this 3rd site is filled with Ca2+ upon
binding or reaction of the Q-substrate, therefore optimizing entrance of the K-substrate.
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Intriguingly, the tall narrow sedimentation peaks of covalently inhibited FXIIIA* (Fig. 23,
Chapter 4) were observed at low 4 mM Ca2+. The close resemblance of those peaks with
the one for free FXIII°,high enzyme may imply that FXIIIA* did bind an additional Ca2+ ion
upon inhibition with the Q-substrate mimic and adopted a conformation similar to
FXIII°,high.
Whether binding of Ca2+ at the 3rd site precedes entrance of the K-substrate during
the normal course of transglutaminase reaction (without inhibitors), is open to speculation.
It seems plausible, however, that at relatively low Ca2+ levels, coordination of this 3rd site
and completion of the hydrophobic pocket is at least partially dependent on the availability
of the K-substrate. It is known that in the absence of K-substrate, a water molecule acts as
an acyl acceptor resulting in net deamidation of the glutamine to glutamate (59). The Ca2+
requirement for deamidation catalyzed by guinea pig liver transglutaminase was
demonstrated to be much lower than that for transamidation (141), thus raising such a
possibility for homologous FXIIIA.
In conditions where Ca2+ concentrations are relatively high, such as in bone ECM,
the 3rd FXIIIA Ca2+ site may already be saturated even in a free enzyme, prior to the Qsubstrate binding. The present kinetic results suggest that this saturation facilitates a
conformation (FXIIIA°,high) that has a weaker affinity for the Q-substrate (indicated by
higher apparent Km in the current study) but provides a mild improvement to reaction
turnover compared to FXIIIA* (higher apparent Vmax). In addition to the stabilizing effect
observed in the current study, the FXIIIA°,high conformation may also favor crosslinking
(transamidation) of the protein substrates over deamidation, which may be especially
relevant in acidic conditions of the bone ECM.
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Overall, the presented research expands the understanding of the functional
outcomes of the FXIII activation pathways. Based on the previous and current results, the
following model of physiological FXIII activation can be envisioned: nonproteolytic
activation proceeds relatively slow, but constantly. High mM Ca2+ levels, such as in bone
ECM, stabilize the FXIIIA°,high form and provide its constitutive activity as part of the
tissue remodeling processes. By contrast, thrombin-mediated AP-removal facilitates
binding of Ca2+ even at low Ca levels, thus promoting fast build up of FXIII crosslinking
activity in plasma. The resultant FXIIIA* species have high affinity towards glutamine
substrates and respond even to low concentrations of these substrates, ensuring clotstabilizing function during blood coagulation. At the same time, the tendency of FXIIIA*
to aggregation may determine its relatively short life time in plasma, providing an efficient
way to prevent detrimental excessive protein crosslinking. Different activation conditions
also result in conformationally different FXIIIA forms thus providing a possible basis for
developing therapeutic strategies for compartment-specific management of FXIIIA
function.1

1

Some contents of this chapter are reproduced from the published manuscript: Anokhin, B.A., Stribinskis,
V., Dean, W.L., and Maurer, M.C. (2017) Activation of factor XIII is accompanied by a change in
oligomerization state. FEBS J 284, 3849-3861.
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CHAPTER 6
STUDYING THE EFFECT OF FXIIIA ACTIVATION RATE
ON FIBRIN CLOT ARCHITECTURE

Introduction
The three key players at the final stage of blood coagulation that participate in
formation of a blood clot include fibrinogen, thrombin, and FXIII. Fibrinogen, a dimer of
trimers (AαBβγ)2, undergoes thrombin mediated cleavage of the N-terminal
fibrinopeptides A and B from the Aα and Bβ chains. The resulting fibrin self-polymerizes
to create a fibrin network (11,12). Simultaneous with cleavage of fibrinogen, FXIIIA is
subjected to proteolytic removal of its activation peptides by thrombin, thus converting to
an active transglutaminase that introduces covalent crosslinks within the fibrin network
(2,4).
The common L34 polymorphism in the FXIII AP is found in about 25% of the
Caucasian population and has been associated with faster activation of FXIII by thrombin
than the more prevalent V34 (88,90,142,143). Kinetic studies with synthetic FXIII
activation peptide sequences revealed that the extra methylene group in FXIII AP L34
generates a thrombin substrate with a strong enhancement in kcat (90,94). Additional
experiments further demonstrated the critical role that the 34 position can play in
controlling thrombin-catalyzed hydrolysis of the FXIII activation peptide segment (9193,96). These experiments resulted in the proposal that the fibrin clot properties could be
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controlled by designing FXIII activation peptide sequences that are easier or more difficult
to be cleaved by thrombin. The current work has focused on examining the effect of FXIIIA
proteolytic activation rate on fibrin clot structure.

Materials and Methods
Materials
Recombinant human thrombin was generously provided by Dr. Enrico Di Cera and
Dr. Leslie Pelc (St. Louis University). Bovine thrombin was purchased from SigmaAldrich. Human FXIII-free peak 1 fibrinogen was purchased from Enzyme Research
Laboratories (South Bend, IN). Plasma from FXIIIA-deficient mice was kindly provided
by Dr. Matthew Flick (Cincinnati Children’s Hospital, Cincinnati, OH). Thrombin
inhibitor PPACK was from Haematologic Technologies (Essex Junction, VT). FXIII AP
variants were recombinantly expressed and purified as described in Chapter 3.

Thrombin-catalyzed cleavage of FXIIIA AP variants
Cleavage of FXIII AP variants was monitored using SDS-PAGE. 1 µM FXIII
V34X variant was incubated in TBS (50 mM Tris Acetate, pH 7.4, 150 mM NaCl) with
30 nM of recombinant human thrombin (WT or I174A) at 37 °C. At different time points
(1, 2, 5, 10, 15, 20, 25, and 30 min), aliquots were withdrawn and supplemented with 6 µM
PPACK. Samples were then mixed with reducing loading buffer and subjected to SDSPAGE using 8% polyacrylamide gels. The cleavage process was monitored by
densitometric analysis using GelAnalyzer 2010 (www.gelanalyzer.com).
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Fibrin crosslinking in the presence of FXIIIA AP variants
Human FXIII-free fibrinogen (1 mg/ml), a recombinant FXIIIA AP variant (V34,
L34, F34, or W34, 50 nM), and recombinant WT human thrombin (12 nM) were incubated
in TBS in the presence of 2.5 mM CaCl2 at 37 °C. At each time point (5−60 min), the
reaction was quenched by addition of reducing loading buffer followed by boiling for 5
min, resulting in full solubilization of the formed clots. Samples were then subjected to
SDS-PAGE on an 8% gel.

Clot turbidity assay
In a quartz cuvette, 0.5 mg/ml FXIII-free human fibrinogen was combined with
100 nM recombinant FXIIIA variant (V34, L34, F34, or W34) in borate buffer (20 mM
boric acid, pH 7.8, 150 mM NaCl) supplemented with 2.5 mM CaCl2. The mixture was
warmed to 37 °C, and clotting was initiated by addition of 5 nM recombinant human
thrombin (WT or I174A). Fibrin polymerization was monitored by increasing turbidity at
340 nm. Control experiments were performed without addition of FXIIIA.

Preparation of fibrin clots for SEM
FXIII-free fibrinogen from human plasma (0.5−2.0 mg/ml) was combined with
recombinant FXIIIA AP variant (L34, V34 or W34, 100 nM) in borate buffer. The mixture
was incubated at 37 °C for 5 min, and the clotting was initiated by addition of recombinant
human thrombin (5−30 nM) and CaCl2 (2.5 mM). Control clot samples were made without
addition of FXIII. Clots were formed in capped microfuge tubes for 2 h at 37 °C. Whole
plasma clots were prepared in the same manner with the following modifications: 13.5 mM
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CaCl2 was used instead of 2.5 mM, to exceed 10.5 mM citrate present in plasma; and
bovine thrombin at 2.1 NIH U/ml (corresponding to approximately 21 nM) was used
instead of recombinant human thrombin.
The gelated clots were rinsed with the buffer and dehydrated in a series of solutions
with increasing ethanol concentrations (10−95% v/v, 10−30 min in each solution, followed
by three changes of 100% ethanol). The ethanol was then replaced with
hexamethyldisilazane (HMDS, two changes). In some experiments, clots were fixed for 30
min in 2% (v/v) solution of glutaraldehyde in the borate buffer prior to ethanol dehydration.
During initial preparative steps, gelated clots remained attached to the walls of
microfuge tubes, and the solutions were changed by simple pipetting, avoiding contact of
the clots with the pipette tip. At later stages of ethanol dehydration, clots detached from
the tube walls and were suspended in the liquid. After ethanol was replaced with HMDS,
clots were transferred onto aluminum stubs and left to air-dry overnight.

SEM analysis of fibrin clots
SEM of fibrin clots was performed at the University of Louisville Huson Imaging
and Characterization facility. For better electron conductivity, samples were sputter-coated
with gold/palladium using argon plasma at 0.1 Torr and 1.3–1.4 kV for 3 min (these
conditions result in deposition of a ~20 nm metal layer). Imaging was conducted in the
EVO or Supra-35 scanning electron microscope (Carl Zeiss) operating in low pressure
mode using the beam accelerating voltage of 1–6 kV.
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Results
Thrombin-catalyzed cleavage of FXIIIA AP variants
In a series of experiments, recombinant FXIIIA AP variants were subjected to
limited proteolysis by thrombin. In full length FXIIIA, cleavage of the activation peptide
by thrombin results in a 4 kDa molecular weight loss, thus cleaved and noncleaved Asubunits could be separated by SDS-PAGE (Fig. 33A). Using densitometric analysis of the
gels, the full length FXIII AP variants were ranked in terms of their cleavage rates by WT
thrombin L34>>V34>F34>>W34 (Fig. 33B, left), a trend similar to that previously
obtained using synthetic activation peptide fragments (91-93,96). For the I174A thrombin
mutant with a modified architecture of the apolar binding site, W34 FXIIIA became the
best substrate of the series (Fig. 33B, right). The rate of W34 AP cleavage by mutant
thrombin was comparable with that of the V34 FXIIIA – WT thrombin pair (Fig. 33B, left),
in further agreement with the synthetic peptide studies.

Fibrin crosslinking by FXIIIA AP variants
The FXIIIA L34, V34, F34, and W34 AP variants were combined with human
FXIII-free fibrinogen and clotting was initiated by addition of WT thrombin and Ca2+. As
expected, the rate of FXIIIA proteolytic activation determined development of the
crosslinking activity (Fig. 34). The fastest cleaved FXIIIA L34 generated both γ-γ and high
molecular weight (HMW) fibrin species already at the early stage (5 min) of the
experiment. Slow cleavage of FXIIIA W34 by thrombin resulted in the slowest appearance
of γ-γ and very little HMW crosslinks. Interestingly, F34 FXIIIA was cleaved by thrombin
slightly slower than V34 (thrombin cleavage figure), however, both variants crosslinked
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Fig. 33. Thrombin-catalyzed cleavage of full length FXIIIA. (A) Representative results of the SDS-PAGE
assay to follow progress of FXIIIA AP variants cleavage by WT thrombin. FXIIIA amino acid residues
of the cleavage site are depicted on the left. ↓ denotes the scissile R37-G38 bond. (B) FXIIIA AP variants
cleavage progress in the presence of WT (left) and I174 mutant thrombin (right) monitored by
densitometric analysis of the gels.

fibrin to a similar extent (Fig. 34). This observation may in part be explained by the fact
that the cleavage of a single AP on dimeric FXIIIA zymogen promotes full activity of both
cleaved and noncleaved A-subunits, as reported in previous studies (14) and described in
Chapter 5 of the present dissertation. In addition, a competition between FXIIIA and
fibrinogen for the thrombin active site may have further masked the difference in V34 and
F34 cleavage rate observed in the absence of fibrinogen. Overall, the results demonstrate
that the rate of FXIIIA activation influences the extent of covalent crosslinking in a
polymerizing fibrin clot.
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Fig. 34. An SDS-PAGE assay to follow covalent fibrin crosslinking by FXIIIA AP variants. Human FXIIIfree fibrinogen was combined with a FXIIIA AP variant, and clotting was initiated by addition of WT
thrombin and CaCl2. On each gel, the “0” time point represents fibrinogen (Aα, Bβ and γ chains are
denoted). As thrombin cleaves fibrinopeptides A and B during conversion of fibrinogen to fibrin, the
resulting fibrin α and β chains have lower molecular weight than their precursors in fibrinogen.
Disappearance of the γ-chains can be observed on the present gels due to their relatively fast conjugation
into covalent γ-γ dimers by FXIIIA. HMW – high molecular weight γ-α and α-α hybrids are also
crosslinked by FXIIIA. * denotes the earliest detection of HMW species during the course of the
crosslinking reaction.
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Monitoring turbidity of fibrin clots
Fibrin polymerization in the presence of WT thrombin, with and without the
presence of FXIIIA AP variants, was monitored photometrically by increasing turbidity at
340 nm. The following parameters were assessed: (i) the lag phase duration, reflecting time
necessary for thrombin to convert fibrinogen to fibrin in quantities sufficient for
polymerization, (ii) polymerization rate, indicated by the velocity of absorbance increase
due to formation of large supramolecular fibrin aggregates (fibers), and (iii) maximal
absorbance at plateau, conventionally correlated with the thickness of the fibers.
In the absence of FXIIIA, the lag time before fibrin polymerization was 45 sec
(Table 4). This lag was extended in the presence of FXIIIA variants, consistent with the
competition between FXIIIA and fibrinogen for thrombin. The polymerization rates,
estimated from the slope of turbidity increase, and the final turbidity values were slightly
lower in the presence of FXIIIA (Fig. 35, Table 4). However, no clear dependence of fibrin
polymerization on the FXIIIA activation rate was observed.
In the presence of I174A thrombin with decreased ability to cleave fibrinogen, the
fibrin formation and gelation proceeded significantly slower than with WT thrombin
(Fig. 35, right, and Table). The lag-time approached 9 min, and compared to the WT
thrombin, fibrin polymerization rate observed with I174A thrombin was significantly
reduced. Interestingly, the presence of FXIIIA had now a more pronounced effect on the
fibrin polymerization resulting in significantly lower achievable turbidity values. The
extent of this effect was clearly dependent on the FXIIIA activation rate: turbidity value
was lowest in the presence of faster-activated W34 FXIIIA, increased in the presence of
slower-activated V34 FXIIIA, and was maximal in the absence of FXIIIA.
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Fig. 35. Fibrin turbidity assay. Human FXIII-free fibrinogen was combined with a FXIIIA AP variant in
a spectrophotometric cuvette, and the clotting was initiated by addition of WT (left) or I174A thrombin
mutant (right) and CaCl2. Fibrin polymerization was monitored by increasing absorbance at 340 nm.
Colored curves represent fibrin turbidity in the presence of the FXIII AP-variants, black curves represent
control experiments without addition of FXIIIA. Note the different duration of experiments with WT (30
min) and I174A thrombin (60 min).

Table 4. Fibrin turbidity parameters.
FXIIIA variant

lag duration, min

Initial

Absorbance at

polymerization

plateau, AU

rate, AU/min
WT thrombin
No FXIIIA

0.75

0.90

0.96

W34

1.14

0.50

0.93

F34

1.13

0.52

0.92

V34

1.05

0.62

0.90

L34

1.30

0.52

0.94

I174A thrombin
No FXIIIA

8.60

0.10

1.50

W34

8.90

0.07

1.13

V34

8.90

0.07

1.40
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SEM analysis of clots formed with purified human fibrinogen
To study the possible effect of FXIIIA crosslinking on the thickness of fibrin fibers,
FXIIIA variants with different activation rates were combined with FXIII-free fibrinogen
purified from human plasma. The clotting was initiated by addition of thrombin and CaCl2.
In initial experiments, clots were fixed with 2% glutaraldehyde upon gelation, followed by
stepwise dehydration with 50, 70, 90, 95, and 100% ethanol, and drying with HMDS. Clots
were sputtered with gold/palladium and imaged in a Zeiss EVO electron microscope at the
beam accelerating voltage of 6 kV. The major area of the clot surface was found to be
covered with a ‘coating’, and the fiber-resembling structures could barely be observed
underneath (Fig. 36A). A limited number of coating-free spots were present revealing the
characteristic network of fibrin fibers (Fig. 36B). Excessive charging, however, prevented
acquisition of clot images of good quality. Since the clots were mounted on to aluminum
stubs before deposition of gold-palladium, the conductive layer would effectively couple
the surface area of the clot with the stub and consequently, with the grounded specimen
stage. Therefore, the charge was likely accumulating relatively far below the surface of the
samples. Reducing beam-sample interaction volume by lowering the accelerating voltage
helped to minimize the charging effect; however, it led to increased noise.
Another instrument, the Zeiss Supra, is a field emission SEM that generates a
narrower electron beam even at low accelerating voltages. Using this instrument, it was
possible to obtain clot images of better quality at low 1–3 kV without significant charge
accumulation. Still, the coating observed on the surface of the clots limited the number of
areas with exposed fibers (Fig. 36C). At higher magnification (Fig. 36D), the fibrin fibers
could be seen ‘stemming’ from the coating suggesting that non-polymerized fibrin

113

Fig. 36. SEM analysis of fibrin clots fixed with glutaraldehyde. (A) A typical view of a fibrin clot surface
with a coating. (B) Coating-free area of the clot revealing the fibrin network. Images A and B were
obtained on the Zeiss Evo at 6 kV. Excessively bright spots on both images and the lack of focus at higher
magnification (B) resulted from accumulation of charge on the specimen. (C) An image obtained using a
thinner clot sample and at a lower (1 kV) accelerating voltage in the Zeiss Supra FESEM, with the coating
still present.

stabilized by glutaraldehyde crosslinking might constitute that coating. Instead of using
glutaraldehyde to preserve the fiber structure, the dehydration procedure was adjusted to
include a smoother ethanol gradient: 10, 20, 30 50, 70, 90, and 100%. As a result, no
coating was observed, and surprisingly, elimination of glutaraldehyde from the sample
preparation did not affect the morphology of fibrin fibers.
Qualitatively similar clot architectures were observed through an entire range of
employed fibrinogen (0.5, 1.0, and 2.0 mg/ml) and thrombin (5, 15, and 30 nM)
concentrations (Appendices 1−4). In general, the fibrin clots were comprised of thin and
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Fig. 37. SEM analysis of fibrin clots. (A) and (B) – representative images of fibrin clots formed in the
presence of FXIIIA AP variants and WT thrombin. (C) and (D) – fibrin clots formed in the presence of
I174 mutant thrombin and FXIIIA AP variants V34 (C) and W34 (D). Clots in images C and D were fixed
with glutaraldehyde.

thick fibers (Fig. 37A). More detailed examination at higher magnifications revealed that
thick fibers resulted from fusion of the thinner fibers (Fig. 37B). Neither the thickness of
individual fibers nor the amount of fused fibers correlated with the extent of covalent fibrin
crosslinking introduced by FXIIIA AP variants. Ironically, major differences between the
V34X clots were global in nature and were observed during the sample preparation process.
In particular, the ability to retain original clot volume during dehydration was associated
with the extent of FXIII-catalyzed crosslinking and increased in order [FXIII-free clots] <
[W34-clots] < [V34-clots] < [L34-clots]. That is, the clots with no or minimal crosslinking
reduced in volume already in the presence of low concentrations of ethanol. By contrast,
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the most crosslinked clots underwent compaction only at higher ethanol concentrations.
Thereby, the tolerance to the presence of increasing ethanol concentrations indicated the
different strengths of the fibrin networks crosslinked by FXIIIA AP variants. Clots formed
in the presence of thrombin mutant I174A demonstrated a similar dependence of native
volume retention on the extent of FXIIIA-catalyzed crosslinking: W34 FXIIIA was
activated by I174A thrombin faster than V34, and the W34-crosslinked clot was
mechanically stronger. The fiber thickness of I174A-clots (Fig. 37C and D) studied by
SEM was similar to that of the clots formed with WT thrombin.

SEM of clots formed with whole plasma
Since no FXIIIA-related differences in fiber thickness and overall clot architectures
were observed in a pure protein system, there was an interest to study clot morphology in
a more physiological whole plasma environment. The first whole clots were made using
plasma from mice with normal FXIII phenotype. Those clots were relatively thick and,
similarly to the pure fibrin clots, underwent charging in the SEM. Cutting the clots into
thinner sections alleviated the charging problem but resulted in artificial smashing of the
fibers in some areas (Fig. 38A). In addition, the excessively dense fiber network
complicated morphological evaluation. A 1:4 dilution of the whole murine plasma resulted
in thinner clots that did not require dissection and had optimal network density (Fig. 38B).
Next, recombinant FXIIIA V34X AP variants were administered into the plasma
from FXIIIA-null mice. Clots formed without FXIIIA significantly ‘flattened’ during the
dehydration process, and thus fibrin fibers on the SEM images (Fig. 39) appear denser
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Fig. 38. SEM of clots formed with whole plasma from WT mice. (A) A dissected clot formed with
undiluted plasma. (B) A thinner clot specimen obtained with 1:4 diluted plasma.

packed. Clots formed in the presence of FXIIIA better retained their three-dimensional
structure throughout the sample preparation process. Analogous to the pure fibrin system,
no confident conclusions could be made on differences in fiber thickness for the clots
crosslinked by FXIII AP-variants. More importantly, however, an increasing amount of
nonfibrous crosslinked protein was observed within the FXIII-containing clots: the least
with the W34 (slow activated) and the most with the L34 (fast activated) FXIII AP-variant
(Fig. 39). Whether this nonfibrous material represents non-polymerized fibrin or other
plasma proteins, it is expected to contribute to overall clot penetrability and mechanical
and fibrinolytic stability.
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Fig. 39. SEM of clots formed with whole plasma (1:4 dilution) from FXIIIA-deficient mice after
administration of exogenous FXIIIA AP variants, as well as control clots without FXIIIA. Two sets of
clots were studied. For each set, clots were made using the plasma from a single mouse (1 and 2).
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Discussion
For a better understanding of FXIIIA function in different physiological contexts,
one needs to consider the peculiarities of FXIIIA activation environments. It is reasonable
to assume that due to highly regulated Ca homeostasis, nonproteolytic activation pathways
leading to FXIIIA°,low and FXIIIA°,high generally operate in a constitutive manner. The
activity of FXIIIA as part of ongoing physiological processes within the cells and in some
extracellular matrices is thereby expected to be relatively constant. In blood plasma, where
concentration of Ca2+ ions is maintained at a low 1.5 mM, constitutive generation of
FXIIIA°,low species is prevented by association of FXIIIA with the inhibitory FXIIIB (64).
In a process that is initiated in exigent cases such as bleeding, the proteolytic removal of
activation peptide prompts fast FXIIIA activation. The complexity of this mechanism
arises from concomitant activation of FXIIIA with proteolytic conversion of fibrinogen to
polymerizing fibrin by the same protease, thrombin (144). In this situation, the rate of
FXIIIA* generation and hence the timing of crosslinking activity introduction may have a
significant impact on the functional outcome of the clotting process, as observed with the
natural L34 FXIIIA polymorphism (88,89).
In previous kinetic studies with synthetic activation peptide sequences (90-94,96),
the Maurer group demonstrated that amino acid residue 34 of the FXIII AP affects the rate
of thrombin-catalyzed cleavage of the R37-G38 peptide bond. Altering the activation
peptide residue 34 was predicted to change the full length FXIIIA activation rate and thus,
to affect the properties of fibrin clot. For experimental validation of the synthetic peptide
predictions, a series of full-length FXIIIA V34X variants was generated. The cleavage rates
of those variants by WT and mutant I174A thrombin constituted trends similar to those
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observed with synthetic peptides. Furthermore in SDS-PAGE experiments, the extent of
fibrin covalent crosslinking correlated with the FXIIIA* generation rate.
Initial attempts of fibrin clot preparation for SEM were conducted following
methodology reported by researchers in the blood coagulation field. The coating, likely
formed by non-polymerized fibrin(ogen), covered the major surface area of the clots, thus
significantly limiting our ability to examine the morphology of the individual fibers. In a
recent publication by Macrae et al. (145), such coating, referred to as fibrin biofilm, was
proposed to be a product of the fibrin clotting. A major concern associated with that study
is the routine use of glutaraldehyde as a fixative agent in clot preparation. As mentioned in
Chapter 2, glutaraldehyde is a protein crosslinker. Thus, fixation with glutaraldehyde
would covalently stabilize non-polymerized fibrin(ogen) at the outer surface of the clot.
Macrae reported that the film formed as a result of fibrin polymerization at the
liquid-air interface. In the current work, such air-liquid interface was also present during
fibrin polymerization. At the final stages of preparation for the SEM, fibrin clots were fully
suspended in dehydrating solutions. Thus, mounting of multiple samples with the surface,
that was air-exposed during clot formation, always facing up is difficult to imagine. Yet,
the fibrin film was consistently observed in all clot samples, thus suggesting that such film
does not necessarily result from fibrin exposure to the air. Furthermore, from analysis of
the clots obtained in the presence of a FXIIIA inhibitor, Macrae and coworkers concluded
that film formation did not require FXIIIA-mediated crosslinking of the fibrin molecules.
However, no control experiments without use of the crosslinker glutaraldehyde were
discussed. In the present work, no film was observed upon elimination of glutaraldehyde
from sample preparation, further supporting the artificial nature of the film. The
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morphology of the fibers that were or were not fixed in glutaraldehyde was similar.
Therefore, the present study demonstrates that the glutaraldehyde fixation, often necessary
to preserve the morphology of cellular structures, does not always benefit preparation of
fibrin clots for SEM analysis. In fact, investigation of the FXIIIA-catalyzed crosslinking
effect would greatly be hindered by introducing artificial crosslinking into the fibrin clot.
Ariёns and coworkers were the first group to employ a combination of solutionbased techniques and SEM to examine the functional significance of the FXIIIA L34
polymorphism (88). This research group demonstrated that the faster activated FXIIIA L34
introduced more covalent crosslinks than the more prevalent V34 variant, thus resulting in
mechanically stronger fibrin clots. The slightly lower turbidity at 340 nm for clots formed
in the presence of L34 was then correlated with thinner fibers observed by SEM. In the
current work, additional FXIIIA X34 variants were generated with a broader range of
activation rates. The extent of covalent fibrin crosslinking was clearly correlated with the
activation rate of FXIIIA AP variants, in a good agreement with observations by Ariёns et
al. Surprisingly, no striking differences were observed between fiber thickness of the clots
formed in the presence of those AP variants and the WT thrombin. Such observation was
further supported by the same fiber thickness in the FXIII-free clots used as a negative
control. Thus, current results suggest that FXIIIA-mediated crosslinking does not have a
major impact on fiber thickness.
An appreciable effect of FXIIIA on clot turbidity could only be seen upon
significant, non-physiological impairment of fibrin generation by the thrombin mutant
I174A. Even with the observed difference in turbidity in solution, SEM analysis of dried
samples did not reveal differences in fiber thickness. Therefore, turbidity at 340 nm likely
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reflected the thickness of undisturbed hydrated fibrin fibers in a stagnant solution. Different
turbidity values obtained with the same starting fibrinogen and thrombin concentrations
would thus correlate with different packing density of protofibrils within the fiber.
Physiologically, this packing density is largely dependent on the efficiency of fibrin
generation by thrombin. In addition, fibrin fibers undergo irreversible compaction as they
form under constant tensile and pressure stresses in the dynamic plasma environment (146).
Possible experimental limitations of the current work could arise from the
fibrinogen preparation used. FXIII-free Peak 1 fibrinogen purified from human plasma
does not contain γ′ chains resulting from alternative mRNA splicing. The γ′ fibrinogen
constitutes 8-15% of the total fibrinogen and has been shown to promote branching of the
fibers in a polymerizing fibrin clot (147-149). Therefore, the absence of γ′ variant could
lead to an altered clot morphology. However, FXIIIA crosslinking is not directed
exclusively to the γ′ fibrin, as indicated by the present SDS-page assay, where crosslinking
could still be observed in the absence of γ′ (Fig. 34).
Hethershaw and coworkers examined clot structure by SEM using the regular γ/γ′
fibrinogen (131). Scrupulous measurements revealed statistically significant differences in
fiber thickness for clots formed in the presence (75 nm) and absence (86 nm) of FXIIIA.
Working with a similar fibrinogen preparation, Ryan et al. (150) reported that inhibition of
FXIII did not affect morphology of the fibers. More profound factors affecting fiber
thickness were the starting concentrations of fibrinogen and thrombin. Increasing those
concentrations led to increased branching, which in turn was correlated with thinner fibers.
It is necessary to acknowledge that such conclusive trends were not observed in the present
study (Appendices 1−4). This lack of observation could be attributed to the narrower range
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of thrombin and fibrinogen concentrations employed, and to the absence of the branchingpromoting γ′ chain.
Examining the function of FXIIIA AP variants in whole plasma overcame
limitations of the pure fibrin system and provided long sought after morphological
evidence of the FXIIIA effect on the clot architecture. Besides fibrin fibers, additional
protein material was revealed by the SEM analysis. By eliminating the artificial
glutaraldehyde crosslinking, it was possible to correlate the amount of this nonfibrous
material in the clots with the activation rate of FXIIIA AP variants. The murine plasma
employed in the current work contained all the physiological protein factors (except the
exogenous FXIIIA). Interestingly, in a proteomic study, Nikolajsen with coworkers (16)
identified 48 different FXIIIA substrates present in the crosslinked plasma clot. Thus, the
currently observed nonfibrous material could originate from the plasma proteins other than
fibrinogen. Regardless of its protein identity, this material significantly contributed to the
overall clot structure observed by SEM, and is expected to further increase the mechanical
strength of non-diluted plasma clots in vivo.
To summarize, the developed V34X full-length protein model allowed
investigation of the effect of timing of FXIIIA activity appearance on the fibrin clot
properties. Present work reveals that the rate of proteolytic FXIIIA activation determines
the extent of covalent fibrin crosslinking that confers increased mechanical strength of the
fibers within a clot. An additional previously overlooked contribution to the clot
architecture is provided by FXIIIA-moderated incorporation of nonfibrous protein within
the fibrin matrix.
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CHAPTER 7
RESEARCH SUMMARY AND FUTURE DIRECTIONS

In recent years, FXIIIA has acquired recognition as a crucial player not only in
blood coagulation but also in nonhemostatic events. Despite previous intensive
investigations of FXIIIA, critical gaps are still present in understanding biochemical
properties of this transglutaminase. FXIIIA is the only member of the transglutaminase
family that exists as a homodimer in the zymogen form. In the absence of structural
information, the active form has long been thought to be a dimer as well. However, given
the proximity of the active sites to the dimer interface, rearrangements would have to occur
for the A-subunits to be able to accommodate two large protein substrates and to release
the crosslinked product. While some computational work has probed these rearrangements,
Chapter 4 of this dissertation describes a series of solution experiments that provide a
simple explanation for the ability of FXIIIA to fulfill its function — the dissociation of A2
homodimer as part of activation. Chapter 5 describes investigations that examine FXIIIA
oligomeric states further to compare the efficiency of proteolytic and nonproteolytic
activation pathways. Nonproteolytic activation is proposed to occur slowly but
constitutively, thus constantly supplying active FXIIIA to fulfill nonhemostatic functions.
The fast build up of FXIIIA activity during thrombin-mediated proteolytic activation
perfectly suits this mechanism to the physiological environment of blood coagulation. A
special interest in this activation pathway arises from the concomitant physiological
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activation of fibrinogen and FXIIIA by thrombin. The V34X model described in Chapter
6 permits efficient manipulation of thrombin’s ability to activate FXIIIA without affecting
the conversion of fibrinogen to fibrin. I now summarize my findings and present
perspectives for future factor XIII research.

Probing FXIIIA conformational rearrangements
A series of solution-based techniques was employed to study changes in the FXIIIA
during its activation. Both proteolytic and nonproteolytic activation resulted in a decrease
of FXIIIA intrinsic tryptophan fluorescence. The fluorescence decrease from that of the
zymogen indicated a change in polarity of the environment surrounding the tryptophan
residues, consistent with their increased solvent exposure. Interestingly in the nPAGE
experiments, activated FXIIIA forms could not be well resolved. Such a change in
electrophoretic mobilities further confirmed global conformational rearrangements that
FXIIIA undergoes during activation. In addition, the observations suggested the critical
importance of Ca2+ for maintaining activated FXIIIA conformation. Size exclusion
chromatography (SEC) revealed different Stokes radii for the zymogen and
nonproteolytically activated forms of FXIIIA. In principle, the SEC elution profile of
activated FXIIIA was consistent with the reduced molecular weight of this form; however
given the asymmetry of FXIIIA globular structure, correlation with the molecular weight
is not possible. Furthermore, SEC could not be successfully utilized for studying thrombinactivated FXIIIA due to heavy precipitation of this species.
Sedimentation velocity AUC experiments provided resolution of both
proteolytically and nonproteolytically activated FXIIIA. Compared to the dimeric
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zymogen FXIIIA (s = 7.9 S), the values for activated FXIIIA were lower (4.6-4.8 S),
indicative of the monomeric state. Notably, the active FXIIIA remained monomeric upon
binding of substrate analogs including the small molecule iodoacetamide and the peptide
K9-DON.
Given the noncovalent stabilization of the dimer, zymogen FXIIIA2 has been
viewed as a self-interacting system in equilibrium. Sedimentation equilibrium AUC
provided an estimated KD of 8 nM for the zymogen FXIIIA2. Sedimentation equilibrium
data for the activated FXIIIA forms were also fitted to the monomer-dimer equilibrium
model, yielding a KD of 90 mM for nonproteolytically activated and 220 mM for
proteolytically activated FXIIIA. Such high mM concentrations required for the interaction
of activated A-subunits are certainly impossible to occur in a physiological setting.
Therefore, sedimentation equilibrium AUC results provided critical support that active
FXIIIA exists as a monomer at physiological concentrations.
A few naturally occurring and experimental amino acid substitutions (R11Q,
R260C, R260L, and G562R) disrupt the dimer interactions in zymogen FXIIIA2. Following
site-directed mutagenesis of the FXIIIA gene, these mutants were expressed as GST-fusion
proteins in E. coli. The mutant FXIIIA proteins were only soluble while still attached to
the dimeric GST-tag. Proteolytic cleavage of GST caused immediate precipitation of
FXIIIA, indicating solution instability of the mutant proteins and stressing the necessity of
the dimeric state for zymogen FXIIIA2. In contrast to amino acid mutations at the dimer
interface, substitution at a more distant site within the catalytic core domain tyrosine 283
(Y283C) caused a significant conformational distortion in the FXIIIA molecule but had a
milder effect on the ability of zymogen to dimerize.
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Experiments presented in this dissertation were performed exclusively on FXIIIA
without its plasma partner FXIIIB. Since dissociation of the B-subunits from the Asubunits after cleavage of the activation peptide has already been well documented, the
physiological presence of FXIIIB is not expected to affect post-cleavage rearrangements
of FXIIIA in plasma. The presence of FXIIIB in the experimental samples would, however,
affect hydrodynamic modeling of the sedimentation data.
Of more interest is the oligomeric state of FXIIIB itself. Plasma FXIII has been
routinely described as a heterocomplex of A2 and B2 dimers. Studies by Chung et al. (73)
and Ichinose et al. (151) suggested the dimeric state for free FXIIIB. These conclusions
were based on gel filtration results, and caution should be taken in correlating protein peak
elution volumes with the molecular weights. This concern is especially important for
FXIIIB, which is even less symmetric than FXIIIA. Moreover, noncovalent dimeric
interaction is concentration-dependent and, while FXIIIB subunits may dimerize at the
relatively high concentrations required for detection by size exclusion chromatography, the
oligomeric state at lower concentrations found in plasma is unknown. Carrel and coworkers
(152) performed electron microscopy and density gradient centrifugation and suggested a
monomeric state for FXIIIB. The Carrell group conclusions were questioned by Bishop et
al. (105) on the basis of incorrect interpretation of the molecular dimensions. Thus, the
dimeric state of FXIIIB has not been conclusively established. The deciphering of the
interactions between the B-subunits and the A-B hetero-associations warrants future
research.
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Dynamic and functional implications of FXIIIA activation pathways
Sedimentation velocity AUC along with catalytic activity assays were employed to
compare FXIIIA forms resulting from different activation pathways. Full proteolytic
activation of FXIIIA could be achieved with physiological thrombin amounts within
minutes. Furthermore, analysis of partially thrombin-activated FXIIIA (approximately half
of the A-subunits cleaved) indicated that for most of the dimeric zymogen species cleavage
of a single activation peptide was sufficient to promote dissociation to monomers. Both
cleaved and noncleaved FXIIIA species possessed equal enzymatic activity. Thus,
proteolysis by thrombin presents the fastest mechanism of FXIIIA activation. However,
the resulting FXIIIA* species tend to aggregate, suggesting a relatively short lifetime of
this FXIIIA form.
The rate of nonproteolytic FXIIIA activation was dependent on the Ca2+
concentration. Incubation of FXIIIA with 100 mM Ca2+ (FXIIIA°,high) resulted in full
dissociation of the A-subunits within 30 min, a rate comparable to proteolytic activation.
At 25 mM Ca2+ — as encountered in the bone ECM, only 20% dissociation of FXIIIA was
observed after 30 min. Unlike, thrombin-activated FXIIIA*, no precipitation of the
FXIIIA°,high form was observed. At 4 mM Ca2+, approximately 20% dissociation of FXIIIA
was only observed after 6 h. Accurate quantitation of monomeric protein became difficult
at longer incubation times due to progressive precipitation of the FXIIIA°,low.
Thus, it was possible to isolate uniformly monomeric FXIIIA* and FXIIIA°,high
forms for further investigation. Comparison of sedimentation properties of these forms
revealed greater conformational heterogeneity for FXIIIA*. The higher solubility of
FXIIIA°,high species was correlated with a greater amount of bound Ca2+. Kinetic
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comparisons of the two FXIIIA forms revealed that FXIIIA* interacts with the glutamine
substrate more readily (indicated by lower apparent Km) than does FXIIIA°,high. The latter,
however, provided slightly faster transglutaminase reaction turnover (higher apparent
Vmax). Therefore, the activity results corroborated proposed conformational and dynamic
differences between the two FXIIIA forms. Interestingly, previous reports suggested
occupancy of two Ca2+ sites in activated FXIIIA molecule. A recently published crystal
structure of FXIIIA°,high with covalently bound inhibitor reveals three Ca2+ binding sites.
With that in mind, the current AUC and activity observations led to a proposal that in the
presence of low mM Ca2+, such as in plasma, saturation of the third Ca2+ site in FXIIIA is
coordinated with binding of the glutamine substrate. By contrast, in environments where
Ca2+ concentration is relatively high, such as bone ECM, the 3rd Ca2+ site may be saturated
even in the free enzyme. This saturation results in lower FXIIIA°,high affinity to the
glutamine substrate but increases the solution stability of this form.
The possibilities raised by observations of the current project call for a more
detailed kinetic evaluation of proteolytically and non-proteolytically activated FXIIIA.
Future research could focus on probing FXIIIA specificity not only for the glutamine but
also for the amine substrates. In the present work, the direct chromogenic assay provided
the best kinetic information; however, the poor solubility of DMPDA along with its
absorbance properties limited the range of concentrations that could be employed in the
assay. Under certain conditions, the kinetic response of FXIIIA to increasing glutamine
substrate concentrations was reminiscent of that for enzymes with negative cooperativity.
Since the current work demonstrated a monomeric state of active FXIIIA, this kinetic
response may suggest hysteresis in FXIIIA catalytic behavior. The limitations of the
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DMPDA assay, however, would not allow such conclusions to be made.
Another activity assay employed is based on detection of the ammonia released
during the transglutaminase reaction. Since this assay does not rely on the chromogenic
amine FXIIIA substrate, different amine donors can be utilized, with a greater
concentration range than is feasible for DMPDA. In the present work, a downside of the
ammonia release assay manifested in the vulnerability of the coupling enzyme glutamate
dehydrogenase to 100 mM Ca2+ required for the FXIIIA°,high form. Additional experiments
indicate that once activated by 100 mM Ca2+ (a quick way to obtain uniformly monomeric
species), the FXIIIA°,high form remains monomeric and demonstrates the same level of
activity even at 25 mM Ca2+. Above all, the coupled ammonia release assay may be used
in future experiments investigating catalytic properties of both FXIIIA* and FXIIIA°,high.
The MDC activity assay qualitatively confirmed the results of the DMPDA assay.
In addition, MDC assay allowed study of FXIIIA catalytic action on the physiological
protein substrate fibrinogen αC at physiological concentrations. However, the MDC assay
in the form employed for current research is demanding in terms of time and labor. Better
throughput may be achieved in future work by direct measurement of the fluorescence of
the reacted glutamine substrate. Instead of electrophoresis, the separation from excess
nonreacted MDC may be achieved by precipitating the protein with trichloroacetic acid
followed by centrifugation. After resuspension of the resulting pellet, the amount of
incorporated MDC can be measured using fluorimetry.
Another aspect that needs more elucidation is binding of Ca2+ by FXIIIA. Available
reports indicate KD values of 100 µM for the first, zymogenic Ca2+ site. The affinities of
the remaining two putative Ca2+ sites in the FXIIIA molecule are unknown. A conventional
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method, such as ITC, may provide reliable information on the stoichiometry of FXIIIA-Ca
interactions and affinities of Ca2+ binding sites. However, a titration approach will only
reveal the Ca2+ amounts that can bind to FXIIIA. For determination of Ca2+ that actually
does bind to FXIIIA under different conditions, the FXIIIA forms would have to be isolated
followed by quantification of bound Ca2+ per weight of the protein. Such isolation of
FXIIIA without loss of the bound Ca2+ seems challenging, if not impossible. More
importantly, and demanding further investigation is the possibility that the binding of Ca2+
by FXIIIA-glutamine substrate complex favors transamidation over deamidation. A series
of kinetic experiments is expected to estimate the effect of Ca2+ concentration on FXIIIA*catalyzed transamidation versus deamidation of the glutamine substrate. A lower Ca2+
requirement for deamidation than transamidation would be consistent with that idea.

V34X model of FXIIIA proteolytic activation
FXIIIA variants with V34X amino acid substitutions were recombinantly expressed
in E. coli. The thrombin-catalyzed cleavage of the V34X variants was monitored by SDSPAGE and densitometric analysis. FXIIIA variants were ranked in terms of their cleavage
rates: L34>>V34>F34>>W34. In a series of fibrin crosslinking assays, FXIIIA variants
were activated by thrombin simultaneously with fibrinogen. Thrombin cleavage rates were
correlated with the extent of covalent crosslinking between fibrin α and γ chains introduced
by V34X variants. A relatively small difference between V34 and F34 cleavage rates did
not lead to distinct differences in fibrin crosslinking by these two variants. Thus, the most
crosslinks were introduced by the fastest activated L34, followed by V34 ≈ F34, and the
least amount of fibrin crosslinking was observed in the presence of slow activated W34
131

FXIIIA.
FXIIIA variants activated faster or slower by thrombin would begin crosslinking at
different stages of fibrin polymerization. The results of fibrin turbidity assays indicated
that the presence of FXIIIA as a competing thrombin substrate slightly delayed and
decelerated the fibrin polymerization. However, a clear dependence of this effect on
FXIIIA activation rate could only be observed upon nonphysiological impairment of fibrin
formation by a mutant I174A thrombin.
SEM analysis of fibrin clots prepared with purified fibrinogen revealed no major
effect of FXIIIA on the fibrin fiber thickness or morphology. Both thick and thin fibers
were observed in the clots regardless of the amount of covalent fibrin crosslinks. Closer
examination revealed that the thicker fibers resulted from fusion of thinner fibers. More
importantly, the glutaraldehyde fixation, routinely used in preparation of clot samples for
SEM, was shown to result in artificial fibrin coating on the clot surface. Elimination of
glutaraldehyde from the sample preparation simplified subsequent imaging of the
specimens without affecting the fibrin network morphology. Still, the extent of fibrin
crosslinking by different FXIIIA variants did not correlate with fiber thickness, although
mechanical strength differences were qualitatively observed. Thus far, the technically
simple SDS-PAGE assay has been the most useful approach for monitoring crosslinking
of fibrin chains and predicting mechanical strength of the fibrin clot.
FXIIIA variants were then introduced into whole plasma from FXIIIA-deficient
mice. SEM analysis of the resulting clots revealed previously overlooked morphological
evidence for incorporation of nonfibrous protein material into the clot. This protein
material may significantly contribute to the mechanical properties of the clot in vivo.

132

Importantly, the extent of the nonfibrous protein incorporation correlated with the FXIIIA
activation rate.
Thus, the tunable FXIII AP sequences allowed ex vivo manipulation of fibrin clot
properties. Besides presenting an efficient experimental model for studying fibrin clotting,
the V34X FXIIIA variants may be implemented in future development of fibrin-based
biomaterials with desired mechanical properties and even tissue engineering. Another
interesting perspective is matching the designed FXIII V34X with thrombin variants.
Thrombin mutants with reduced procoagulant activity have been developed to hinder the
extent of fibrin clotting (153,154). Current interest is in testing the ability of those
anticoagulant thrombins to activate FXIIIA V34X variants thus still allowing non-fibrin
crosslinking reactions to occur. As an example in the present work, I174A thrombin
cleaved fibrinogen significantly slower than the WT thrombin, but efficiently activated
W34 FXIIIA. Such a mutant thrombin-FXIIIA pair may provide an additional benefit of
normal FXIIIA crosslinking activity in environments with reduced fibrin coagulation.
Further screening of thrombin-FXIIIA combinations is suggested as an immediate
continuation of the current research project.
Final opinion:
On the prospective pharmaceutical targeting of FXIIIA
The presented research was aimed to explore uncharacterized fundamental
properties of FXIIIA, and through such exploration, expand the current understanding of
FXIIIA physiological function. A retrospective evaluation of the entire investigation leads
to a recurrent notion that it is the activation pathway diversity that makes FXIIIA stand out
among the transglutaminase family of enzymes. This activation diversity may be a key to
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differential therapeutic targeting of FXIIIA function in a variety of pathophysiological
events, a concept yet to be recognized and addressed in pharmaceutical development.
The thrombin activated FXIIIA* form currently presents the most attractive
pharmacological target. However, not only has the FXIIIA* been elusive from
crystallographic efforts, but also a challenging subject of solution experiments.
Nevertheless, once the conformational difference between FXIIIA* and FXIII°,high is
recognized, it is possible to overcome the lack of detailed structural information and begin
searching for pharmaceutical agents that specifically target either form. The crystal
structures of non-proteolytically activated FXIII°,high in complexes with inhibitors are
available from the Stieler group (PDB 4KTY, 5MHM, 5 MHN, 5MHO). It is then feasible
to screen active site targeting compounds that will confer specificity to FXIIIA°,high and
eliminate those affecting the FXIIIA*. Should this orthosteric design fail, a search for
allosteric effectors may be more successful. Previous studies in the Maurer group involving
chemical modification and hydrogen-deuterium exchange suggested better solvent
accessibility of the β-sandwich region of FXIIIA*, while β-barrel 1 was more solventexposed in FXIIIA°,high. These local structural differences may serve as a starting point for
allosteric targeting of FXIIIA.
Therapeutic specificity towards the coagulation-active FXIIIA* may be achieved
by controlling its proteolytic activation. In this work, the variation in FXIIIA* generation
rate has been demonstrated to affect fibrin crosslinking. Faster proteolytic activation (and
hence, greater amount of FXIIIA*) during blood coagulation results in a larger extent of
fibrin crosslinking and incorporation of other proteins into the clot. In this direction,
allosteric agents specifically limiting thrombin’s ability to activate FXIIIA and not
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fibrinogen, may be promising. The V34X activation model provides an interesting basis
for development of anticoagulants. The tunable XVPR↓G amino acid sequence may serve
as a prodrug linker whose cleavage by active thrombin will release the pharmaceutical
agent, such as recombinant plasmin, at a desirable rate and specifically at the clotting site.
This approach would also ensure that neither FXIIIA°,low nor FXIIIA°,high are affected.
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APPENDIX 5
Abbreviations
FXIII
RBC
TF
ECM
DIC
COL 1
pFN
TG2
AUC
SV
SE
SEM
HMDS
WT
PSP
GST
TBS
AP
PPACK
DMSO
DON
IAA
PBS
SEC
nPAGE
FXIIIA*
FXIIIA°,low
FXIIIA°,high
MDC
DMPDA
GEE
GDH
HMW
FESEM

Coagulation factor XIII
Red blood cells
Tissue factor
Extracellular matrix
Disseminated intravascular coagulation
Type 1 collagen
Plasma fibronectin
Transglutaminase 2
Analytical ultracentrifugation
Sedimentation velocity
Sedimentation equilibrium
Scanning electron microscopy
hexamethyldisilazane
Wild type
PreScission protease
Glutathione S-transferase
Tris buffered saline
Activation peptide
D-phenylalanyl-prolyl-arginyl chloromethyl ketone
Dimethyl sulfoxide
6-diazo-5-oxo-norleucine
Iodoacetamide
Phosphate buffered saline
Size exclusion chromatography
Non-denaturing polyacrylamide gel electrophoresis
FXIIIA activated by thrombin in the presence of 4 mM Ca2+
FXIIIA activated nonproteolytically by low mM Ca2+
FXIIIA activated nonproteolytically by high (>25 mM) Ca2+
Monodansylcadaverine
N,N-dimethyl-1,4-phenylenediamine
Glycine ethyl ester
Glutamate dehydrogenase
High molecular weight
Field emission scanning electron microscope
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Oligomeric state of blood coagulation Factor XIIIA (plasma transglutaminase)
• Employed gel electrophoresis, size exclusion chromatography, analytical
ultracentrifugation, and site-directed mutagenesis along with recombinant protein
expression in E. coli.
• Demonstrated for the first time that homodimeric zymogen Factor XIIIA dissociates into
monomers upon activation and transitions to an active transglutaminase. Proposed
stabilizing role of dimeric state of the zymogen in a physiological setting.
Proteolytic and nonproteolytic activation of Factor XIIIA
• Employed a series of enzymatic evaluations (spectrophotometric, end-point SDS-PAGE
assays).
• Demonstrated that proteolytic activation of Factor XIIIA by thrombin is more efficient
than nonproteolytic activation by Ca2+ ions.
• Revealed that nonproteolytically activated FXIIIA is less accessible for its substrates than
proteolytically activated enzyme.
• In a physiological context, proteolytical activation results in fast build up of FXIIIA
fibrin-stabilizing activity. Nonproteolytically activated FXIIIA exhibits low constitutive
activity in non-coagulation environments. Observed differences between the two active
forms may serve as a basis for compartment-specific pharmaceutical management of
FXIIIA function.
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Influence of Factor XIII on fibrin clot architecture
• Generated FXIIIA activation peptide substitutions (Val 34 Xaa) with altered activation
rates.
• Employed electrophoretic assays to demonstrate different extents of fibrin crosslinking
by these Factor XIIIA variants.
• Introduced FXIIIA Val 34 Xaa variants into murine FXIIIA-deficient plasma. Studied
morphology of the resulting clots using scanning electron microscopy. Demonstrated that
FXIIIA activation kinetics directly impacts the structure and stability of a fibrin clot.
Perm State University, Perm, Russia
Undergraduate and graduate research, 2003-2013
Research programs in microbiology:
Mechanisms of Alkanotrophic Rhodococcus Adaptation to Hostile Environments;
Phthalic Acid Utilization by Soil Heterotrophic Bacteria.
• Employed conventional microbiological methods, HPLC, gas chromatography, PCR, and
DNA sequencing.
• Characterized adaptive role of morphogenic developmental cycle of Rhodococcus
actinobacteria.
• Isolated and characterized bacterial strains capable of biodegradation of xenobiotic
compounds.
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156

RECENT CONFERENCE PARTICIPATION
1. 32nd Annual Symposium of The Protein Society, July 2018, Boston, MA.
Anokhin B.A., Dean W.L., Maurer M.C. Activation pathway diversity as a basis for
functional regulation of coagulation Factor XIII. [Poster]
2. 62nd Annual Meeting of Biophysical Society, February 2018, San Francisco, CA.
Anokhin B.A., Stribinskis V., Dean W.L., Maurer M.C. Dissociation of Factor XIII
homodimer during activation process: solution evidence weighs in on decades-long debate.
[Poster]
3. 6th Bluegrass Molecular Biophysics Symposium, May 2017, Lexington, KY.
Anokhin B.A., Maurer M.C. Probing the oligomerization of Factor XIIIA in a solution
environment. [Oral presentation]
4. Gordon Research Conference Hemostasis, July 2016, Stowe, VT.
Anokhin B.A., Maurer M.C. Probing the oligomerization of Factor XIIIA in a solution
environment. [Poster]
Professional Membership
Biophysical Society; The Protein Society
Teaching experience
- Chemistry 201 (General Chemistry) 2013, 2014
- Chemistry 546 (Biochemistry Laboratory) 2014, 2016
- Assisted in mentoring for undergraduate projects (7 undergraduate students)
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